000081695612/312022Q3FALSEhttp://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member00008169562022-01-012022-09-3000008169562022-10-24xbrli:shares00008169562022-07-012022-09-30iso4217:USD00008169562021-07-012021-09-3000008169562021-01-012021-09-30iso4217:USDxbrli:shares00008169562022-09-3000008169562021-12-310000816956us-gaap:CommonStockMember2021-12-310000816956us-gaap:AdditionalPaidInCapitalMember2021-12-310000816956us-gaap:RetainedEarningsMember2021-12-310000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000816956us-gaap:TreasuryStockMember2021-12-310000816956us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000816956us-gaap:TreasuryStockMember2022-01-012022-03-3100008169562022-01-012022-03-310000816956us-gaap:RetainedEarningsMember2022-01-012022-03-310000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000816956us-gaap:AdditionalPaidInCapitalMemberus-gaap:AccountingStandardsUpdate202006Member2022-03-310000816956us-gaap:RetainedEarningsMemberus-gaap:AccountingStandardsUpdate202006Member2022-03-310000816956us-gaap:AccountingStandardsUpdate202006Member2022-03-310000816956us-gaap:CommonStockMember2022-03-310000816956us-gaap:AdditionalPaidInCapitalMember2022-03-310000816956us-gaap:RetainedEarningsMember2022-03-310000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000816956us-gaap:TreasuryStockMember2022-03-3100008169562022-03-310000816956us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300000816956us-gaap:TreasuryStockMember2022-04-012022-06-3000008169562022-04-012022-06-300000816956us-gaap:RetainedEarningsMember2022-04-012022-06-300000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000816956us-gaap:CommonStockMember2022-06-300000816956us-gaap:AdditionalPaidInCapitalMember2022-06-300000816956us-gaap:RetainedEarningsMember2022-06-300000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000816956us-gaap:TreasuryStockMember2022-06-3000008169562022-06-300000816956us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000816956us-gaap:TreasuryStockMember2022-07-012022-09-300000816956us-gaap:RetainedEarningsMember2022-07-012022-09-300000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000816956us-gaap:CommonStockMember2022-09-300000816956us-gaap:AdditionalPaidInCapitalMember2022-09-300000816956us-gaap:RetainedEarningsMember2022-09-300000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000816956us-gaap:TreasuryStockMember2022-09-300000816956us-gaap:CommonStockMember2020-12-310000816956us-gaap:AdditionalPaidInCapitalMember2020-12-310000816956us-gaap:RetainedEarningsMember2020-12-310000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000816956us-gaap:TreasuryStockMember2020-12-3100008169562020-12-310000816956us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310000816956us-gaap:TreasuryStockMember2021-01-012021-03-3100008169562021-01-012021-03-310000816956us-gaap:RetainedEarningsMember2021-01-012021-03-310000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310000816956us-gaap:CommonStockMember2021-03-310000816956us-gaap:AdditionalPaidInCapitalMember2021-03-310000816956us-gaap:RetainedEarningsMember2021-03-310000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310000816956us-gaap:TreasuryStockMember2021-03-3100008169562021-03-310000816956us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300000816956us-gaap:TreasuryStockMember2021-04-012021-06-3000008169562021-04-012021-06-300000816956us-gaap:RetainedEarningsMember2021-04-012021-06-300000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000816956us-gaap:CommonStockMember2021-06-300000816956us-gaap:AdditionalPaidInCapitalMember2021-06-300000816956us-gaap:RetainedEarningsMember2021-06-300000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000816956us-gaap:TreasuryStockMember2021-06-3000008169562021-06-300000816956us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000816956us-gaap:TreasuryStockMember2021-07-012021-09-300000816956us-gaap:RetainedEarningsMember2021-07-012021-09-300000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000816956us-gaap:CommonStockMember2021-09-300000816956us-gaap:AdditionalPaidInCapitalMember2021-09-300000816956us-gaap:RetainedEarningsMember2021-09-300000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300000816956us-gaap:TreasuryStockMember2021-09-3000008169562021-09-300000816956us-gaap:AccountingStandardsUpdate202006Member2022-01-010000816956cnmd:A2.625PercentConvertibleNotesDue2024Memberus-gaap:ConvertibleNotesPayableMember2019-01-29xbrli:pure0000816956us-gaap:AccountingStandardsUpdate202006Member2022-01-012022-03-310000816956cnmd:A2.625PercentConvertibleNotesDue2024Memberus-gaap:ConvertibleNotesPayableMember2022-06-062022-06-060000816956cnmd:A2.625PercentConvertibleNotesDue2024Memberus-gaap:ConvertibleNotesPayableMember2022-09-300000816956cnmd:In2BonesGlobalIncMember2022-06-132022-06-130000816956cnmd:In2BonesGlobalIncMember2022-06-130000816956cnmd:BiorezIncMember2022-08-092022-08-090000816956cnmd:BiorezIncMember2022-08-090000816956cnmd:In2BonesGlobalIncMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-06-130000816956cnmd:BiorezIncMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-08-090000816956cnmd:In2BonesGlobalIncMemberus-gaap:CustomerRelationshipsMember2022-06-130000816956cnmd:BiorezIncMemberus-gaap:CustomerRelationshipsMember2022-08-090000816956us-gaap:TrademarksAndTradeNamesMembercnmd:In2BonesGlobalIncMember2022-06-130000816956cnmd:BiorezIncMemberus-gaap:TrademarksAndTradeNamesMember2022-08-090000816956cnmd:In2BonesGlobalIncMemberus-gaap:CustomerRelationshipsMember2022-06-132022-06-130000816956cnmd:In2BonesGlobalIncMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-06-132022-06-130000816956cnmd:BiorezIncMemberus-gaap:TrademarksAndTradeNamesMember2022-08-092022-08-090000816956cnmd:BiorezIncMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-08-092022-08-090000816956us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueMeasurementsRecurringMembercnmd:In2BonesGlobalIncMember2022-06-130000816956us-gaap:FairValueInputsLevel3Membercnmd:BiorezIncMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueMeasurementsRecurringMember2022-08-090000816956us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembercnmd:In2BonesGlobalIncMembercnmd:MeasurementInputRevenueVolatilityMember2022-06-130000816956us-gaap:FairValueInputsLevel3Membercnmd:BiorezIncMemberus-gaap:FairValueMeasurementsRecurringMembercnmd:MeasurementInputRevenueVolatilityMember2022-08-090000816956cnmd:In2BonesGlobalIncMember2022-07-012022-09-300000816956cnmd:In2BonesGlobalIncMember2022-06-132022-09-300000816956cnmd:OrthopedicSurgeryMembercountry:US2022-07-012022-09-300000816956country:UScnmd:GeneralSurgeryMember2022-07-012022-09-300000816956country:US2022-07-012022-09-300000816956cnmd:OrthopedicSurgeryMembercountry:US2021-07-012021-09-300000816956country:UScnmd:GeneralSurgeryMember2021-07-012021-09-300000816956country:US2021-07-012021-09-300000816956us-gaap:EMEAMembercnmd:OrthopedicSurgeryMember2022-07-012022-09-300000816956us-gaap:EMEAMembercnmd:GeneralSurgeryMember2022-07-012022-09-300000816956us-gaap:EMEAMember2022-07-012022-09-300000816956us-gaap:EMEAMembercnmd:OrthopedicSurgeryMember2021-07-012021-09-300000816956us-gaap:EMEAMembercnmd:GeneralSurgeryMember2021-07-012021-09-300000816956us-gaap:EMEAMember2021-07-012021-09-300000816956srt:AsiaPacificMembercnmd:OrthopedicSurgeryMember2022-07-012022-09-300000816956srt:AsiaPacificMembercnmd:GeneralSurgeryMember2022-07-012022-09-300000816956srt:AsiaPacificMember2022-07-012022-09-300000816956srt:AsiaPacificMembercnmd:OrthopedicSurgeryMember2021-07-012021-09-300000816956srt:AsiaPacificMembercnmd:GeneralSurgeryMember2021-07-012021-09-300000816956srt:AsiaPacificMember2021-07-012021-09-300000816956cnmd:OrthopedicSurgeryMembercnmd:AmericasexcludingtheUnitedStatesMember2022-07-012022-09-300000816956cnmd:AmericasexcludingtheUnitedStatesMembercnmd:GeneralSurgeryMember2022-07-012022-09-300000816956cnmd:AmericasexcludingtheUnitedStatesMember2022-07-012022-09-300000816956cnmd:OrthopedicSurgeryMembercnmd:AmericasexcludingtheUnitedStatesMember2021-07-012021-09-300000816956cnmd:AmericasexcludingtheUnitedStatesMembercnmd:GeneralSurgeryMember2021-07-012021-09-300000816956cnmd:AmericasexcludingtheUnitedStatesMember2021-07-012021-09-300000816956cnmd:OrthopedicSurgeryMember2022-07-012022-09-300000816956cnmd:GeneralSurgeryMember2022-07-012022-09-300000816956cnmd:OrthopedicSurgeryMember2021-07-012021-09-300000816956cnmd:GeneralSurgeryMember2021-07-012021-09-300000816956cnmd:OrthopedicSurgeryMemberus-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300000816956us-gaap:TransferredAtPointInTimeMembercnmd:GeneralSurgeryMember2022-07-012022-09-300000816956us-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300000816956cnmd:OrthopedicSurgeryMemberus-gaap:TransferredAtPointInTimeMember2021-07-012021-09-300000816956us-gaap:TransferredAtPointInTimeMembercnmd:GeneralSurgeryMember2021-07-012021-09-300000816956us-gaap:TransferredAtPointInTimeMember2021-07-012021-09-300000816956cnmd:OrthopedicSurgeryMemberus-gaap:TransferredOverTimeMember2022-07-012022-09-300000816956cnmd:GeneralSurgeryMemberus-gaap:TransferredOverTimeMember2022-07-012022-09-300000816956us-gaap:TransferredOverTimeMember2022-07-012022-09-300000816956cnmd:OrthopedicSurgeryMemberus-gaap:TransferredOverTimeMember2021-07-012021-09-300000816956cnmd:GeneralSurgeryMemberus-gaap:TransferredOverTimeMember2021-07-012021-09-300000816956us-gaap:TransferredOverTimeMember2021-07-012021-09-300000816956cnmd:OrthopedicSurgeryMembercountry:US2022-01-012022-09-300000816956country:UScnmd:GeneralSurgeryMember2022-01-012022-09-300000816956country:US2022-01-012022-09-300000816956cnmd:OrthopedicSurgeryMembercountry:US2021-01-012021-09-300000816956country:UScnmd:GeneralSurgeryMember2021-01-012021-09-300000816956country:US2021-01-012021-09-300000816956us-gaap:EMEAMembercnmd:OrthopedicSurgeryMember2022-01-012022-09-300000816956us-gaap:EMEAMembercnmd:GeneralSurgeryMember2022-01-012022-09-300000816956us-gaap:EMEAMember2022-01-012022-09-300000816956us-gaap:EMEAMembercnmd:OrthopedicSurgeryMember2021-01-012021-09-300000816956us-gaap:EMEAMembercnmd:GeneralSurgeryMember2021-01-012021-09-300000816956us-gaap:EMEAMember2021-01-012021-09-300000816956srt:AsiaPacificMembercnmd:OrthopedicSurgeryMember2022-01-012022-09-300000816956srt:AsiaPacificMembercnmd:GeneralSurgeryMember2022-01-012022-09-300000816956srt:AsiaPacificMember2022-01-012022-09-300000816956srt:AsiaPacificMembercnmd:OrthopedicSurgeryMember2021-01-012021-09-300000816956srt:AsiaPacificMembercnmd:GeneralSurgeryMember2021-01-012021-09-300000816956srt:AsiaPacificMember2021-01-012021-09-300000816956cnmd:OrthopedicSurgeryMembercnmd:AmericasexcludingtheUnitedStatesMember2022-01-012022-09-300000816956cnmd:AmericasexcludingtheUnitedStatesMembercnmd:GeneralSurgeryMember2022-01-012022-09-300000816956cnmd:AmericasexcludingtheUnitedStatesMember2022-01-012022-09-300000816956cnmd:OrthopedicSurgeryMembercnmd:AmericasexcludingtheUnitedStatesMember2021-01-012021-09-300000816956cnmd:AmericasexcludingtheUnitedStatesMembercnmd:GeneralSurgeryMember2021-01-012021-09-300000816956cnmd:AmericasexcludingtheUnitedStatesMember2021-01-012021-09-300000816956cnmd:OrthopedicSurgeryMember2022-01-012022-09-300000816956cnmd:GeneralSurgeryMember2022-01-012022-09-300000816956cnmd:OrthopedicSurgeryMember2021-01-012021-09-300000816956cnmd:GeneralSurgeryMember2021-01-012021-09-300000816956cnmd:OrthopedicSurgeryMemberus-gaap:TransferredAtPointInTimeMember2022-01-012022-09-300000816956us-gaap:TransferredAtPointInTimeMembercnmd:GeneralSurgeryMember2022-01-012022-09-300000816956us-gaap:TransferredAtPointInTimeMember2022-01-012022-09-300000816956cnmd:OrthopedicSurgeryMemberus-gaap:TransferredAtPointInTimeMember2021-01-012021-09-300000816956us-gaap:TransferredAtPointInTimeMembercnmd:GeneralSurgeryMember2021-01-012021-09-300000816956us-gaap:TransferredAtPointInTimeMember2021-01-012021-09-300000816956cnmd:OrthopedicSurgeryMemberus-gaap:TransferredOverTimeMember2022-01-012022-09-300000816956cnmd:GeneralSurgeryMemberus-gaap:TransferredOverTimeMember2022-01-012022-09-300000816956us-gaap:TransferredOverTimeMember2022-01-012022-09-300000816956cnmd:OrthopedicSurgeryMemberus-gaap:TransferredOverTimeMember2021-01-012021-09-300000816956cnmd:GeneralSurgeryMemberus-gaap:TransferredOverTimeMember2021-01-012021-09-300000816956us-gaap:TransferredOverTimeMember2021-01-012021-09-300000816956us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-12-310000816956us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000816956us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000816956us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-01-012022-09-300000816956us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-09-300000816956us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-300000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000816956us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-09-300000816956us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300000816956us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300000816956us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-12-310000816956us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000816956us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000816956us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-01-012021-09-300000816956us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-09-300000816956us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-09-300000816956us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000816956us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-09-300000816956us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-300000816956us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300000816956us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2022-09-300000816956us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2021-12-310000816956us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-09-300000816956us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2021-12-310000816956us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-09-300000816956us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-01-012022-09-300000816956cnmd:RevenuesMember2022-07-012022-09-300000816956cnmd:RevenuesMember2021-07-012021-09-300000816956us-gaap:CostOfSalesMember2022-07-012022-09-300000816956us-gaap:CostOfSalesMember2021-07-012021-09-300000816956cnmd:RevenuesMember2022-01-012022-09-300000816956cnmd:RevenuesMember2021-01-012021-09-300000816956us-gaap:CostOfSalesMember2022-01-012022-09-300000816956us-gaap:CostOfSalesMember2021-01-012021-09-300000816956us-gaap:ForeignExchangeForwardMember2022-07-012022-09-300000816956us-gaap:ForeignExchangeForwardMember2021-07-012021-09-300000816956us-gaap:ForeignExchangeForwardMember2022-01-012022-09-300000816956us-gaap:ForeignExchangeForwardMember2021-01-012021-09-300000816956us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-09-300000816956us-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-09-300000816956us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-09-300000816956us-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2022-09-300000816956us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000816956us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000816956us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000816956us-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2021-12-310000816956cnmd:A2250PercentConvertibleNotesDue2027Memberus-gaap:ConvertibleNotesPayableMember2022-06-060000816956cnmd:A2.625PercentConvertibleNotesDue2024Membercnmd:HedgeTransactionsMemberus-gaap:ConvertibleNotesPayableMember2019-01-292019-01-290000816956us-gaap:WarrantMembercnmd:A2.625PercentConvertibleNotesDue2024Memberus-gaap:ConvertibleNotesPayableMember2019-01-292019-01-290000816956cnmd:A2250PercentConvertibleNotesDue2027Membercnmd:HedgeTransactionsMemberus-gaap:ConvertibleNotesPayableMember2022-06-062022-06-060000816956us-gaap:WarrantMembercnmd:A2250PercentConvertibleNotesDue2027Memberus-gaap:ConvertibleNotesPayableMember2022-06-062022-06-060000816956srt:WeightedAverageMember2022-01-012022-09-300000816956srt:WeightedAverageMembercnmd:CustomerandDistributorRelationshipsMember2022-01-012022-09-300000816956cnmd:CustomerandDistributorRelationshipsMember2022-09-300000816956cnmd:CustomerandDistributorRelationshipsMember2021-12-310000816956srt:WeightedAverageMembercnmd:SalesrepresentationmarketingandpromotionalrightsMember2022-01-012022-09-300000816956cnmd:SalesrepresentationmarketingandpromotionalrightsMember2022-09-300000816956cnmd:SalesrepresentationmarketingandpromotionalrightsMember2021-12-310000816956srt:WeightedAverageMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-01-012022-09-300000816956us-gaap:TechnologyBasedIntangibleAssetsMember2022-09-300000816956us-gaap:TechnologyBasedIntangibleAssetsMember2021-12-310000816956cnmd:PatentsAndOtherIntangibleAssetsMembersrt:WeightedAverageMember2022-01-012022-09-300000816956cnmd:PatentsAndOtherIntangibleAssetsMember2022-09-300000816956cnmd:PatentsAndOtherIntangibleAssetsMember2021-12-310000816956us-gaap:TrademarksAndTradeNamesMember2022-09-300000816956us-gaap:TrademarksAndTradeNamesMember2021-12-310000816956cnmd:ExpenseMember2022-09-300000816956cnmd:ReductionofRevenueMember2022-09-300000816956us-gaap:LineOfCreditMember2022-09-300000816956us-gaap:LineOfCreditMember2021-12-310000816956us-gaap:LoansPayableMember2022-09-300000816956us-gaap:LoansPayableMember2021-12-310000816956cnmd:A2.625PercentConvertibleNotesDue2024Memberus-gaap:ConvertibleNotesPayableMember2021-12-310000816956cnmd:A2250PercentConvertibleNotesDue2027Memberus-gaap:ConvertibleNotesPayableMember2022-09-300000816956cnmd:A2250PercentConvertibleNotesDue2027Memberus-gaap:ConvertibleNotesPayableMember2021-12-310000816956us-gaap:LoansPayableMembercnmd:AmendedAndRestatedSeniorCreditAgreementMember2021-07-160000816956us-gaap:LineOfCreditMembercnmd:AmendedAndRestatedSeniorCreditAgreementMember2021-07-160000816956us-gaap:LoansPayableMembercnmd:AmendedAndRestatedSeniorCreditAgreementMember2022-01-012022-09-300000816956us-gaap:LongTermDebtMemberus-gaap:LondonInterbankOfferedRateLIBORMembercnmd:AmendedAndRestatedSeniorCreditAgreementMember2022-01-012022-09-300000816956us-gaap:LongTermDebtMembercnmd:AmendedAndRestatedSeniorCreditAgreementMember2022-09-300000816956us-gaap:LongTermDebtMemberus-gaap:FederalFundsEffectiveSwapRateMembercnmd:AmendedAndRestatedSeniorCreditAgreementMember2022-01-012022-09-300000816956us-gaap:LongTermDebtMembercnmd:AdjustedLIBORMembercnmd:AmendedAndRestatedSeniorCreditAgreementMember2022-01-012022-09-300000816956cnmd:A2.625PercentConvertibleNotesDue2024Memberus-gaap:ConvertibleNotesPayableMember2019-01-292019-01-290000816956cnmd:A2.625PercentConvertibleNotesDue2024Memberus-gaap:CallOptionMemberus-gaap:ConvertibleNotesPayableMember2019-01-290000816956cnmd:A2.625PercentConvertibleNotesDue2024Memberus-gaap:ConvertibleNotesPayableMember2022-01-012022-09-300000816956cnmd:A2.625PercentConvertibleNotesDue2024Memberus-gaap:ConvertibleNotesPayableMember2021-07-012021-09-300000816956cnmd:A2.625PercentConvertibleNotesDue2024Memberus-gaap:ConvertibleNotesPayableMember2021-01-012021-09-300000816956cnmd:A2.625PercentConvertibleNotesDue2024Memberus-gaap:ConvertibleNotesPayableMember2022-07-012022-09-300000816956cnmd:A2250PercentConvertibleNotesDue2027Memberus-gaap:ConvertibleNotesPayableMember2022-06-062022-06-060000816956cnmd:A2250PercentConvertibleNotesDue2027Memberus-gaap:CallOptionMemberus-gaap:ConvertibleNotesPayableMember2022-06-060000816956cnmd:A2250PercentConvertibleNotesDue2027Memberus-gaap:ConvertibleNotesPayableMember2022-07-012022-09-300000816956cnmd:A2250PercentConvertibleNotesDue2027Memberus-gaap:ConvertibleNotesPayableMember2022-01-012022-09-3000008169562022-06-060000816956us-gaap:OtherExpenseMember2022-01-012022-09-3000008169562022-06-062022-06-060000816956us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300000816956us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300000816956us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300000816956us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300000816956us-gaap:OtherExpenseMember2022-07-012022-09-300000816956us-gaap:OtherExpenseMember2021-07-012021-09-300000816956us-gaap:OtherExpenseMember2021-01-012021-09-300000816956cnmd:LiquidatedDamagesMembercnmd:EndoDynamixInc.Memberus-gaap:PendingLitigationMember2017-01-182017-01-180000816956cnmd:AdditionalDamagesMembercnmd:EndoDynamixInc.Memberus-gaap:PendingLitigationMember2017-01-182017-01-18

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period endedCommission File Number
September 30, 2022001-39218
CONMED CORPORATION
(Exact name of the registrant as specified in its charter)
Delaware16-0977505
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
11311 Concept BlvdLargo,Florida33773
(Address of principal executive offices)(Zip Code)
(727) 392-6464
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.01 par valueCNMDNYSE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒   No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  

Yes ☒   No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company.  See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act (Check one).

Large accelerated filer ☒    Accelerated filer ☐    Non-accelerated filer ☐

Smaller reporting company ☐    Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒

The number of shares outstanding of registrant's common stock, as of October 24, 2022 is 30,482,412 shares.


CONMED CORPORATION
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2022
PART I FINANCIAL INFORMATION
Item NumberPage
   
 
   
 
   
 
   
 
   
 
   
   
   
   
   
PART II OTHER INFORMATION
   
   
   

PART I FINANCIAL INFORMATION
Item 1.
CONMED CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Unaudited, in thousands except per share amounts)
 
 Three Months EndedNine Months Ended
 September 30,September 30,
 2022202120222021
Net sales$275,088 $248,827 $794,605 $736,665 
Cost of sales123,473 106,521 355,222 324,485 
Gross profit151,615 142,306 439,383 412,180 
Selling and administrative expense114,600 104,736 333,302 307,476 
Research and development expense12,767 10,859 34,932 32,203 
  Operating expenses127,367 115,595 368,234 339,679 
Income from operations24,248 26,711 71,149 72,501 
Interest expense8,536 8,145 19,462 27,917 
Other expense— 1,127 112,011 1,127 
Income (loss) before income taxes15,712 17,439 (60,324)43,457 
Provision (benefit) for income taxes(30,438)2,491 46,842 5,359 
Net income (loss)$46,150 $14,948 $(107,166)$38,098 
Comprehensive income (loss)$43,125 $13,756 $(113,096)$42,242 
Per share data: 
Net income (loss) 
Basic$1.51 $0.51 $(3.59)$1.31 
Diluted1.48 0.47 (3.59)1.19 
Weighted average common shares
Basic30,473 29,179 29,892 29,097 
Diluted31,103 32,143 29,892 32,020 

 See notes to consolidated condensed financial statements.
1
CONMED CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(Unaudited, in thousands except share and per share amounts)
 
September 30,
2022		December 31,
2021
ASSETS 
Current assets: 
Cash and cash equivalents$33,354 $20,847 
Accounts receivable, net197,287 183,882 
Inventories304,813 231,644 
Prepaid expenses and other current assets38,789 23,750 
Total current assets574,243 460,123 
Property, plant and equipment, net113,720 108,863 
Goodwill814,260 617,528 
Other intangible assets, net689,453 471,049 
Other assets100,368 108,454 
Total assets$2,292,044 $1,766,017 
LIABILITIES AND SHAREHOLDERS' EQUITY 
Current liabilities: 
Current portion of long-term debt$237 $12,249 
Accounts payable74,228 58,197 
Accrued compensation and benefits54,095 60,488 
Other current liabilities80,019 65,712 
Total current liabilities208,579 196,646 
Long-term debt1,036,438 672,407 
Deferred income taxes112,578 68,537 
Other long-term liabilities218,112 42,992 
Total liabilities1,575,707 980,582 
Commitments and contingencies
Shareholders' equity: 
Preferred stock, par value $0.01 per share;
 
authorized 500,000 shares; none outstanding
— — 
Common stock, par value $0.01 per share;
100,000,000 shares authorized; 31,299,194 shares
issued in 2022 and 2021, respectively
313 313 
Paid-in capital407,095 396,771 
Retained earnings392,144 496,605 
Accumulated other comprehensive loss(60,133)(54,203)
Less: 822,438 and 1,925,893 shares of common stock
in treasury, at cost, in 2022 and 2021, respectively
(23,082)(54,051)
Total shareholders’ equity716,337 785,435 
Total liabilities and shareholders’ equity$2,292,044 $1,766,017 

 See notes to consolidated condensed financial statements.
2

CONMED CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF SHAREHOLDERS' EQUITY
(Unaudited, in thousands except per share amounts)
 Common StockPaid-in
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss		Treasury
Stock		Shareholders’
Equity
 SharesAmount
Balance at December 31, 202131,299 $313 $396,771 $496,605 $(54,203)$(54,051)$785,435 
Common stock issued under employee plans  2,232  4,020 6,252 
Stock-based compensation  4,463    4,463 
Dividends on common stock ($0.20 per share)
(5,899)(5,899)
Comprehensive income (loss):
Cash flow hedging gain, net1,082 
Pension liability, net521 
Foreign currency translation adjustments(163)
Net income14,975 
Total comprehensive income16,415 
Cumulative effect of change in accounting principle(1)
(37,911)20,791 (17,120)
Balance at March 31, 202231,299 $313 $365,555 $526,472 $(52,763)$(50,031)$789,546 
Common stock issued under employee plans611 633 1,244 
Stock-based compensation5,755 5,755 
Dividends on common stock ($0.20 per share)
(6,092)(6,092)
Shares issued for the settlement of convertible notes(25,890)25,890 — 
Convertible note premium on extinguishment103,125 103,125 
Settlement of convertible notes hedge transactions118,912 118,912 
Settlement of warrants(96,758)(96,758)
Issuance of convertible notes hedge transactions, net of tax(142,128)(142,128)
Issuance of warrants72,000 72,000 
Comprehensive income (loss):
Cash flow hedging gain, net4,662 
Pension liability, net490 
Foreign currency translation adjustments(9,497)
Net loss(168,291)
Total comprehensive loss(172,636)
Balance at June 30, 202231,299 $313 $401,182 $352,089 $(57,108)$(23,508)$672,968 
Common stock issued under employee plans159 426 585 
Stock-based compensation5,754 5,754 
Dividends on common stock ($0.20 per share)
(6,095)(6,095)
Comprehensive income (loss):
Cash flow hedging gain, net4,833 
Pension liability, net490 
Foreign currency translation adjustments(8,348)
Net income46,150 
Total comprehensive income43,125 
Balance at September 30, 202231,299 $313 $407,095 $392,144 $(60,133)$(23,082)$716,337 
(1)We recorded the cumulative impact of adopting ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity in 2022. Refer to Note 3 for further detail.

3
 Common StockPaid-in
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss		Treasury
Stock		Shareholders’
Equity
 SharesAmount
Balance at December 31, 202031,299 $313 $382,628 $457,417 $(63,681)$(67,639)$709,038 
Common stock issued under employee plans  2,944  5,271 8,215 
Stock-based compensation  3,387    3,387 
Dividends on common stock ($0.20 per share)
(5,813)(5,813)
Comprehensive income (loss):
Cash flow hedging gain, net3,926 
Pension liability, net631 
Foreign currency translation adjustments(3,674)
Net income9,860 
Total comprehensive income10,743 
Balance at March 31, 202131,299 $313 $388,959 $461,464 $(62,798)$(62,368)$725,570 
Common stock issued under employee plans  414  2,312 2,726 
Stock-based compensation  4,290    4,290 
Dividends on common stock ($0.20 per share)
(5,830)(5,830)
Comprehensive income (loss):
Cash flow hedging gains, net1,221 
Pension liability, net631 
Foreign currency translation adjustments2,601 
Net income13,290 
Total comprehensive income17,743 
Balance at June 30, 202131,299 $313 $393,663 $468,924 $(58,345)$(60,056)$744,499 
Common stock issued under employee plans  (3,180) 2,118 (1,062)
Stock-based compensation  4,327    4,327 
Dividends on common stock ($0.20 per share)
(5,837)(5,837)
Comprehensive income (loss):
Cash flow hedging gain, net2,917 
Pension liability, net631 
Foreign currency translation adjustments(4,740)
Net income14,948 
Total comprehensive income13,756 
Balance at September 30, 202131,299 $313 $394,810 $478,035 $(59,537)$(57,938)$755,683 

See notes to consolidated condensed financial statements.

4
CONMED CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
 Nine Months Ended
 September 30,
 20222021
Cash flows from operating activities: 
Net income (loss)$(107,166)$38,098 
Adjustments to reconcile net income (loss) to net cash provided by operating activities: 
Depreciation12,028 12,519 
Amortization of debt discount— 7,611 
Amortization of deferred debt issuance costs3,404 2,946 
Amortization39,754 40,747 
Stock-based compensation15,972 12,003 
Deferred income taxes38,442 (1,311)
Loss on early extinguishment of debt3,426 899 
Loss on convertible notes conversion premium103,125 — 
Loss on convertible notes hedge transactions settlement5,460 — 
Increase (decrease) in cash flows from changes in assets and liabilities:  
Accounts receivable(16,092)9,890 
Inventories(52,126)(34,679)
Accounts payable14,475 (6,223)
Accrued compensation and benefits(8,261)5,030 
Other assets(11,710)(15,915)
Other liabilities4,232 6,370 
Net cash provided by operating activities44,963 77,985 
Cash flows from investing activities: 
Purchases of property, plant and equipment(16,109)(11,678)
Payments related to business acquisition, net of cash acquired(227,102)— 
Net cash used in investing activities(243,211)(11,678)
Cash flows from financing activities: 
Payments on term loan(92,981)(63,673)
Proceeds from term loan— 52,411 
Payments on revolving line of credit(404,000)(272,753)
Proceeds from revolving line of credit317,000 236,753 
Payments to redeem convertible notes(275,000)— 
Proceeds from issuance of convertible notes800,000 — 
Payments related to debt issuance costs(21,830)(2,000)
Dividends paid on common stock(17,865)(17,418)
Purchases of convertible notes hedge transactions(187,600)— 
Proceeds from issuance of warrants72,000 — 
Proceeds from settlement of convertible notes hedge transactions86,228 — 
Payment for settlement of warrants(69,534)— 
Other, net7,067 5,921 
Net cash provided by (used in) financing activities213,485 (60,759)
Effect of exchange rate changes on cash and cash equivalents(2,730)(1,393)
Net increase in cash and cash equivalents12,507 4,155 
Cash and cash equivalents at beginning of period20,847 27,356 
Cash and cash equivalents at end of period$33,354 $31,511 
Non-cash investing and financing activities:
Contingent consideration$183,914 $— 
Dividends payable$6,095 $5,837 
See notes to consolidated condensed financial statements.
5
CONMED CORPORATION
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(Unaudited, in thousands except per share amounts)

Note 1 – Operations

CONMED Corporation (“CONMED”, the “Company”, “we” or “us”) is a medical technology company that provides surgical devices and equipment for minimally invasive procedures.  The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology.

Note 2 - Interim Financial Information

The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for annual financial statements. The information herein reflects all normal recurring material adjustments, which are, in the opinion of management, necessary to fairly present the results for the periods presented. The consolidated condensed financial statements herein consist of all wholly-owned domestic and foreign subsidiaries with all significant intercompany transactions eliminated. Results for the period ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.

The consolidated condensed financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes for the year ended December 31, 2021 included in our Annual Report on Form 10-K.

Use of Estimates

Preparation of the consolidated condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated condensed financial statements and the reported amounts of revenue and expenses during the reporting period.

Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. We are not aware of any specific event or circumstance that would require an update to our estimates or judgments or a revision of the carrying value of our assets or liabilities as of October 27, 2022, the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.

Note 3 – New Accounting Pronouncements
    
Recently Adopted Accounting Standards

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity ("ASU 2020-06"), which simplifies the accounting for convertible instruments by removing certain separation models requiring separate accounting for embedded conversion features which will result in more convertible debt instruments accounted for as a single liability. The ASU eliminates certain settlement conditions that are required for equity classification to qualify for the derivative scope exception. The ASU addresses how convertible instruments are accounted for in the calculation of diluted earnings per share by using the if-converted method. The ASU is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company adopted this standard on January 1, 2022 using the modified retrospective method. The adoption of this new guidance resulted in:

•an increase of approximately $22.6 million to long-term debt in the consolidated condensed balance sheets, to reflect the full principal amount of the convertible notes then outstanding net of issuance costs (the "2.625% Notes" described more fully in Note 11);
•a reduction of approximately $37.9 million to additional paid-in capital, net of income tax effects, to remove the equity component separately recorded for the conversion features associated with the 2.625% Notes;
•a decrease to deferred income tax liabilities of approximately $5.5 million, and
6
•a cumulative-effect adjustment of approximately $20.8 million, net of income tax effects, to the beginning balance of retained earnings as of January 1, 2022.

The adoption of this new guidance reduced interest expense related to amortization of debt discount on the 2.625% Notes by approximately $2.6 million during the three months ended March 31, 2022. Additionally, the dilutive share count increased by approximately 2.5 million shares as a result of calculating the impact of dilution from the 2.625% Notes using the if-converted method. During the nine months ended September 30, 2022, the Company repurchased and extinguished $275.0 million principal value of the 2.625% Notes as further discussed in Note 11. Concurrently, the Company entered into a Supplemental Indenture related to the remaining $70.0 million in 2.625% Notes, pursuant to which the Company irrevocably elected to settle the principal value of those 2.625% Notes in cash. As a result, in periods in which the Company has net income, only the conversion premium will affect the dilutive share count. During the three months ended September 30, 2022, our average share price exceeded the conversion price of the 2.625% Notes and we included such shares assumed to be issued if the Notes were converted in our diluted share count. Refer to Note 9 for further details. As the Company was in a net loss position for the nine months ended September 30, 2022, there were no dilutive potential shares included in the computation of diluted shares outstanding for the nine months ended September 30, 2022.

Recently Issued Accounting Standards, Not Yet Adopted
    
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional guidance if certain criteria are met for entities that have contracts, hedging relationships, and other transactions that reference LIBOR or other reference rates expected to be discontinued as a result of reference rate reform. This ASU is effective as of March 12, 2020 through December 31, 2022. The Company has not adopted this ASU as of September 30, 2022. Our seventh amended and restated senior credit agreement includes language to address the change from LIBOR to an alternative base rate, therefore we do not believe reference rate reform will have a significant impact on our consolidated financial statements, however will continue to monitor our transition away from LIBOR and the potential to elect to apply this guidance in our consolidated financial statements in the event that we are impacted by reference rate reform.

Note 4 - Business Combinations

On June 13, 2022, we acquired In2Bones Global, Inc. ("In2Bones") and all of its stock (the "In2Bones Acquisition") for an aggregate upfront payment of $145.2 million in cash. In addition, there are potential earn-out payments to In2Bones’ equity holders in an amount up to $110.0 million based on the achievement of certain revenue targets for In2Bones products during the sixteen (16) successive quarters commencing on July 1, 2022. In2Bones is a global developer, manufacturer and distributor of medical devices for the treatment of disorders and injuries of the upper (hand, wrist and elbow) and lower (foot and ankle) extremities. The In2Bones Acquisition was funded through a combination of cash on hand and long-term borrowings as further described in Note 11.

On August 9, 2022, we acquired Biorez, Inc. ("Biorez") and all of its stock (the "Biorez Acquisition") for an aggregate upfront payment of $85.9 million in cash. We paid $83.1 million upon closing, with a $2.8 million purchase price adjustment holdback, pursuant to the merger agreement for the Biorez Acquisition. In addition, there are potential earn-out payments to Biorez’ equity holders in an amount up to $165.0 million based on the achievement of certain revenue targets for Biorez products during the sixteen (16) successive quarters commencing on October 1, 2022. Biorez is a medical device start-up focused on advancing the healing of soft tissue using its proprietary BioBrace® implant technology. The Biorez Acquisition was funded through a combination of cash on hand and long-term borrowings.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as a result of the In2Bones and Biorez Acquisitions that were accounted for as business combinations. The assessment of fair value is based on preliminary valuations and estimates that were available to management at the time the consolidated condensed financial statements were prepared. Accordingly, the allocation of purchase price is preliminary and therefore subject to adjustment during the measurement adjustment period.
7
In2BonesBiorez
Cash$445 $742 
Accounts receivable, net5,036 318 
Inventories24,247 61 
Prepaid expenses and other current assets403 118 
Current assets30,131 1,239 
Goodwill139,816 59,176 
Developed technology37,300 176,300 
Distributor relationships27,600 — 
Trademarks and tradenames— 1,600 
Other long-term assets2,875 112 
Total assets acquired$237,722 $238,427 
Current liabilities assumed5,972 1,441 
Deferred income taxes16,699 36,621 
Contingent consideration69,402 114,512 
Other long-term liabilities466 — 
Total liabilities assumed$92,539 $152,574 
Net assets acquired$145,183 $85,853 
    
The goodwill recorded as part of the In2Bones Acquisition primarily represents revenue synergies, the related cost to enter into this new product offering and the In2Bones assembled workforce. Goodwill is not deductible for tax purposes. In2Bones distributor relationships and developed technology are each being amortized over a weighted average life of 15 years.

The goodwill recorded as part of the Biorez Acquisition primarily represents revenue synergies, the related cost to enter into this new product offering and the Biorez assembled workforce. Goodwill is not deductible for tax purposes. Biorez developed technology and trademarks and tradenames are each being amortized over a weighted average life of 20 years.

The contingent consideration was recorded at fair value at the date of acquisition based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues. The recurring Level 3 fair value measurements of contingent consideration for which the liability is recorded include the following significant unobservable inputs:

Assumptions
Unobservable InputIn2BonesBiorez
Discount rate5.67%10.34%
Revenue volatility12.75%18.87%
Projected year of payment
2023-2026
2023-2026

We recorded $10.0 million in net sales for In2Bones products during the third quarter and a total of $12.1 million in net sales since the date of acquisition, June 13, 2022. The net sales were recorded in the consolidated condensed statements of comprehensive income (loss) for the three and nine months ended September 30, 2022, respectively. Earnings recorded in the consolidated condensed statements of comprehensive income (loss) for the three and nine months ended September 30, 2022 were not material. We also believe the proforma information is immaterial for disclosure for the three and nine months ended September 30, 2022 and 2021.

Net sales and earnings for Biorez were immaterial to both the three and nine months ended September 30, 2022. We also believe the proforma information is immaterial for disclosure for the three and nine months ended September 30, 2022 and 2021.


8
Note 5 - Revenues
    
The following tables present revenue disaggregated by primary geographic market where the products are sold, by product line and timing of revenue recognition:
Three Months EndedThree Months Ended
September 30, 2022September 30, 2021
 Orthopedic SurgeryGeneral SurgeryTotalOrthopedic SurgeryGeneral SurgeryTotal
Primary Geographic Markets
United States$45,688 $110,033 $155,721 $37,957 $98,444 $136,401 
Europe, Middle East & Africa26,914 20,300 47,214 24,155 19,905 44,060 
Asia Pacific28,242 17,223 45,465 27,517 16,113 43,630 
Americas (excluding the United States)17,774 8,914 26,688 16,122 8,614 24,736 
Total sales from contracts with customers$118,618 $156,470 $275,088 $105,751 $143,076 $248,827 
Timing of Revenue Recognition
Goods transferred at a point in time$108,875 $154,856 $263,731 $96,389 $141,798 $238,187 
Services transferred over time9,743 1,614 11,357 9,362 1,278 10,640 
Total sales from contracts with customers$118,618 $156,470 $275,088 $105,751 $143,076 $248,827 

Nine Months EndedNine Months Ended
September 30, 2022September 30, 2021
Orthopedic SurgeryGeneral SurgeryTotalOrthopedic SurgeryGeneral SurgeryTotal
Primary Geographic Markets
United States$124,097 $312,034 $436,131 $115,864 $288,069 $403,933 
Europe, Middle East & Africa88,955 63,093 152,048 77,327 58,594 135,921 
Asia Pacific79,333 46,379 125,712 80,403 44,911 125,314 
Americas (excluding the United States)53,932 26,782 80,714 47,215 24,282 71,497 
Total sales from contracts with customers$346,317 $448,288 $794,605 $320,809 $415,856 $736,665 
Timing of Revenue Recognition
Goods transferred at a point in time$317,140 $443,629 $760,769 $291,728 $412,298 $704,026 
Services transferred over time29,177 4,659 33,836 29,081 3,558 32,639 
Total sales from contracts with customers$346,317 $448,288 $794,605 $320,809 $415,856 $736,665 

Contract liability balances related to the sale of extended warranties to customers are as follows:

September 30, 2022December 31, 2021
Contract liability$17,551 $16,760 
    
Revenue recognized during the nine months ended September 30, 2022 and September 30, 2021 from amounts included in contract liabilities at the beginning of the period were $9.5 million and $8.4 million, respectively. There were no material contract assets as of September 30, 2022 and December 31, 2021.

9
Note 6 – Comprehensive Income (Loss)

Comprehensive income (loss) consists of the following:
 
Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Net income (loss)$46,150 $14,948 $(107,166)$38,098 
Other comprehensive income (loss):
Cash flow hedging gain, net of income tax (income tax expense of $1,546 and $929 for the three months ended September 30, 2022 and 2021, respectively, and $3,384 and $2,568 for the nine months ended September 30, 2022 and 2021, respectively)
4,833 2,917 10,577 8,064 
Pension liability, net of income tax (income tax expense of $157 and $201 for the three months ended September 30, 2022 and 2021, respectively, and $439 and $603 for the nine months ended September 30, 2022 and 2021, respectively)
490 631 1,502 1,893 
Foreign currency translation adjustment(8,348)(4,740)(18,009)(5,813)
Comprehensive income (loss)$43,125 $13,756 $(113,096)$42,242 

Accumulated other comprehensive loss consists of the following:

Cash Flow
Hedging
Gain (Loss)		Pension
Liability		Cumulative
Translation
Adjustments		Accumulated
Other
Comprehensive
Income (Loss)
Balance, December 31, 2021$3,656 $(29,671)$(28,188)$(54,203)
Other comprehensive income (loss) before reclassifications, net of tax18,711 — (18,009)702 
Amounts reclassified from accumulated other comprehensive income (loss) before taxa
(10,736)1,941 — (8,795)
Income tax 2,602 (439)— 2,163 
Net current-period other comprehensive income (loss)10,577 1,502 (18,009)(5,930)
Balance, September 30, 2022$14,233 $(28,169)$(46,197)$(60,133)

Cash Flow
Hedging
Gain (Loss)		Pension
Liability		Cumulative
Translation
Adjustments		Accumulated
Other
Comprehensive
Income (Loss)
Balance, December 31, 2020$(5,945)$(36,620)$(21,116)$(63,681)
Other comprehensive income (loss) before reclassifications, net of tax5,141 — (5,813)(672)
Amounts reclassified from accumulated other comprehensive income before taxa
3,854 2,496 — 6,350 
Income tax (931)(603)— (1,534)
Net current-period other comprehensive income (loss)8,064 1,893 (5,813)4,144 
Balance, September 30, 2021$2,119 $(34,727)$(26,929)$(59,537)
(a) The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income (loss) components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 7 and Note 13, respectively, for further details.

10
Note 7 – Fair Value of Financial Instruments
 
 We enter into derivative instruments for risk management purposes only. We operate internationally and, in the normal course of business, are exposed to fluctuations in interest rates, foreign exchange rates and commodity prices. These fluctuations can increase the costs of financing, investing and operating the business. We use forward contracts, a type of derivative instrument, to manage certain foreign currency exposures.
 
By nature, all financial instruments involve market and credit risks. We enter into forward contracts with major investment grade financial institutions and have policies to monitor the credit risk of those counterparties. While there can be no assurance, we do not anticipate any material non-performance by any of these counterparties.
 
Foreign Currency Forward Contracts. We hedge forecasted intercompany sales denominated in foreign currencies through the use of forward contracts.  We account for these forward contracts as cash flow hedges.  To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in current earnings but are included in accumulated other comprehensive loss.  These changes in fair value will be recognized into earnings as a component of sales or cost of sales when the forecasted transaction occurs.  

We also enter into forward contracts to exchange foreign currencies for United States dollars in order to hedge our currency transaction exposures on intercompany receivables designated in foreign currencies.  These forward contracts settle each month at month-end, at which time we enter into new forward contracts.  We have not designated these forward contracts as hedges and have not applied hedge accounting to them.  

The following table presents the notional contract amounts for forward contracts outstanding:

As of
FASB ASC Topic 815 DesignationSeptember 30, 2022December 31, 2021
Forward exchange contractsCash flow hedge$196,749 $172,894 
Forward exchange contractsNon-designated37,057 38,897 

The remaining time to maturity as of September 30, 2022 is within two years for hedge designated foreign exchange contracts and approximately one month for non-hedge designated forward exchange contracts.

11
Statement of comprehensive income (loss) presentation

Derivatives designated as cash flow hedges

Foreign exchange contracts designated as cash flow hedges had the following effects on accumulated other comprehensive income (loss) ("AOCI") and net earnings (loss) on our consolidated condensed statements of comprehensive income (loss) and our consolidated condensed balance sheets:

Amount of Gain Recognized in AOCIConsolidated Condensed Statements of Comprehensive Income (Loss)Amount of Gain (Loss) Reclassified from AOCI
Three Months Ended September 30,
Total Amount of Line Item Presented
Derivative Instrument20222021Location of amount reclassified2022202120222021
Foreign exchange contracts$11,695 $3,188 Net Sales$275,088 $248,827 $5,090 $(1,077)
 Cost of Sales123,473 106,521 225 419 
Pre-tax gain (loss)$11,695 $3,188 $5,315 $(658)
Tax expense (benefit)2,835 770 1,288 (159)
Net gain (loss)$8,860 $2,418 $4,027 $(499)

Amount of Gain Recognized in AOCIConsolidated Condensed Statements of Comprehensive Income (Loss)Amount of Gain (Loss) Reclassified from AOCI
Nine Months Ended September 30,
Total Amount of Line Item Presented
Derivative Instrument20222021Location of amount reclassified2022202120222021
Foreign exchange contracts$24,698 $6,778 Net Sales$794,605 $736,665 $10,237 $(4,948)
Cost of Sales355,222 324,485 499 1,094 
Pre-tax gain (loss)$24,698 $6,778 $10,736 $(3,854)
Tax expense (benefit)5,987 1,637 2,602 (931)
Net gain (loss)$18,711 $5,141 $8,134 $(2,923)
At September 30, 2022, $11.9 million of net unrealized gains on forward contracts accounted for as cash flow hedges, and included in accumulated other comprehensive loss, are expected to be recognized in earnings in the next twelve months.

12
Derivatives not designated as cash flow hedges

Net gains and losses from derivative instruments not accounted for as hedges and losses on our intercompany receivables on our consolidated condensed statements of comprehensive income (loss) were:

Three Months Ended September 30,Nine Months Ended September 30,
Derivative InstrumentLocation on Consolidated Condensed Statements of Comprehensive Income (Loss)2022202120222021
  
Net gain (loss) on currency forward contractsSelling and administrative expense$892 $(48)$1,088 $(398)
Net loss on currency transaction exposuresSelling and administrative expense$(1,110)$(441)$(2,874)$(1,320)

Balance sheet presentation

We record these forward foreign exchange contracts at fair value. The following tables summarize the fair value for forward foreign exchange contracts outstanding at September 30, 2022 and December 31, 2021:

September 30, 2022Location on Consolidated Condensed Balance SheetAsset Fair ValueLiabilities Fair ValueNet
Fair
Value
Derivatives designated as hedged instruments:   
Foreign exchange contractsPrepaid expenses and other current assets$15,922 $(172)$15,750 
Foreign exchange contractsOther long-term assets3,097 (59)3,038 
$19,019 $(231)$18,788 
Derivatives not designated as hedging instruments:   
Foreign exchange contractsOther current liabilities53 (124)(71)
Total derivatives$19,072 $(355)$18,717 

December 31, 2021Location on Consolidated Condensed Balance SheetAsset Fair ValueLiabilities Fair ValueNet
Fair
Value
Derivatives designated as hedged instruments:  
Foreign exchange contracts Prepaid expenses and other current assets$5,331 $(430)$4,901 
Foreign exchange contractsOther long-term liabilities82 (161)(79)
$5,413 $(591)$4,822 
Derivatives not designated as hedging instruments:  
Foreign exchange contractsOther current liabilities38 (180)(142)
Total derivatives$5,451 $(771)$4,680 

13
Our forward foreign exchange contracts are subject to a master netting agreement and qualify for netting in the consolidated condensed balance sheets.
 
Fair Value Disclosure. FASB guidance defines fair value and establishes a framework for measuring fair value and related disclosure requirements. This guidance applies when fair value measurements are required or permitted. The guidance indicates, among other things, that a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. Fair value is defined based upon an exit price model.

Valuation Hierarchy. A valuation hierarchy was established for disclosure of the inputs to the valuations used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from or corroborated by observable market data through correlation. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. There have been no significant changes in the assumptions.
 
Valuation Techniques. Assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2022 consist of forward foreign exchange contracts. The Company values its forward foreign exchange contracts using quoted prices for similar assets. The most significant assumption is quoted currency rates. The value of the forward foreign exchange contract assets and liabilities were valued using Level 2 inputs and are listed in the table above.  The Company values contingent consideration using Level 3 inputs. These include pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input that is unobservable.
    
The carrying amounts reported in our consolidated condensed balance sheets for cash and cash equivalents, accounts receivable, accounts payable and variable long-term debt approximate fair value.  

Note 8 - Inventories

Inventories consist of the following:

September 30,
2022		December 31,
2021
Raw materials$111,431 $83,386 
Work-in-process26,967 17,449 
Finished goods166,415 130,809 
Total$304,813 $231,644 
 
Note 9 – Earnings (Loss) Per Share

Basic earnings (loss) per share (“basic EPS”) is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (“diluted EPS”) gives effect to all dilutive potential shares. As the Company was in a net loss position for the nine months ended September 30, 2022, there were no dilutive potential shares included in the computation of diluted shares outstanding for the nine months ended September 30, 2022.

14
The following table sets forth the computation of basic and diluted earnings (loss) per share for the three and nine months ended September 30, 2022 and 2021:

Three Months Ended September 30, 2022Three Months Ended September 30, 2021
 Basic EPSAdjustmentsDiluted EPSBasic EPSAdjustmentsDiluted EPS
Net income$46,150 — $46,150 $14,948 — $14,948 
Weighted average shares outstanding30,473 — 30,473 29,179 — 29,179 
Employee stock compensation— 585 585 — 1,252 1,252 
Warrants— — — — 468 468 
Convertible notes— 45 45 — 1,244 1,244 
30,473 630 31,103 29,179 2,964 32,143 
EPS$1.51 $1.48 $0.51 $0.47 
 
Nine Months Ended September 30, 2022Nine Months Ended September 30, 2021
 Basic EPSAdjustmentsDiluted EPSBasic EPSAdjustmentsDiluted EPS
Net income (loss)$(107,166)— $(107,166)$38,098 — $38,098 
Weighted average shares outstanding29,892 — 29,892 29,097 — 29,097 
Employee stock compensation— — — — 1,283 1,283 
Warrants— — — — 427 427 
Convertible notes— — — — 1,213 1,213 
29,892 — 29,892 29,097 2,923 32,020 
EPS$(3.59)$(3.59)$1.31 $1.19 

The shares used in the calculation of diluted EPS exclude employee stock options and stock appreciation rights to purchase shares where the exercise price was greater than the average market price of common shares for the period and the effect of the inclusion would be anti-dilutive. Such shares aggregated approximately 2.0 million for the three months ended September 30, 2022 and 0.7 million and 0.5 million for the three and nine months ended September 30, 2021, respectively. As the Company was in a net loss position for the nine months ended September 30, 2022, there were no anti-dilutive shares.

The 2.625% Notes and 2.250% convertible notes due in 2027 (the "2.250% Notes"), more fully described in Note 11, are convertible under certain circumstances, as defined in the respective indentures for each series of notes, into a combination of cash and CONMED common stock.  The following is intended to describe the impact of the 2.625% Notes and 2.250% Notes and related hedge transactions on the calculation of diluted EPS. Additional shares to be issued pursuant to the terms of the 2.625% Notes, the 2.250% Notes and related hedge transactions, if any, would occur at settlement.

15
Effective with our adoption of ASU 2020-06 on January 1, 2022 (see Note 3), the Company began using the if-converted method to compute diluted EPS. Under the if-converted method, in the calculation of diluted EPS, the numerator is adjusted for interest expense applicable to the convertible notes (net of tax) and the denominator is adjusted to include additional common shares assuming the principal portion of the notes and the conversion premium are settled in common shares, when permitted or required. Under the if-converted method, when convertible notes require the principal to be paid in cash, then only the conversion premium affects the calculation of diluted EPS.

On June 6, 2022, the Company repurchased and extinguished $275.0 million principal value of 2.625% Notes as further discussed in Note 11. Concurrently, the Company entered into a Supplemental Indenture related to the remaining $70.0 million in 2.625% Notes, pursuant to which the Company irrevocably elected to settle the principal value of the 2.625% Notes in cash. Similarly, the 2.250% Notes, issued on June 6, 2022, require the principal to be paid in cash. As a result, in periods in which the Company has net income, only the conversion premium will affect dilutive share count. Accordingly, for periods prior to adoption of ASU 2020-06 on January 1, 2022 and after June 6, 2022, in periods in which the Company has net income, the calculation of diluted EPS includes potential diluted shares upon conversion of the 2.625% Notes and the 2.250% Notes, only when the average market price per share of our common stock for the period is greater than the conversion price and only for the conversion premium, with the principal portion required to be settled in cash.

We have entered into convertible notes hedge transactions to increase the effective conversion price of the 2.625% Notes from $88.80 to $114.92.  However, our convertible notes hedges are not included when calculating potential dilutive shares since their effect is always anti-dilutive. Concurrent with entering into the hedge transactions, we entered into warrant transactions under which we agreed to sell shares of our common stock at $114.92. In periods in which the Company has net income, the calculation of diluted EPS includes potential diluted shares to be issued under the warrants when the average market price per share of our common stock for the period is greater than $114.92, calculated under the treasury stock method.

On June 6, 2022, we entered into convertible notes hedge transactions to increase the effective conversion price of the 2.250% Notes from $145.33 to $251.53. However, our convertible notes hedges are not included when calculating potential dilutive shares since their effect is always anti-dilutive. Concurrent with entering into the hedge transactions, we entered into warrant transactions under which we agreed to sell shares of our common stock at $251.53. In periods in which the Company has net income, the calculation of diluted EPS includes potential diluted shares to be issued under the warrants when the average market price per share of our common stock for the period is greater than $251.53, calculated under the treasury stock method.


Note 10 – Goodwill and Other Intangible Assets

The changes in the net carrying amount of goodwill for the nine months ended September 30, 2022 are as follows:

Balance as of December 31, 2021$617,528 
Goodwill resulting from business acquisitions198,992 
Foreign currency translation(2,260)
Balance as of September 30, 2022$814,260 
Assets and liabilities of acquired businesses are recorded at their estimated fair values as of the date of acquisition.  Goodwill represents costs in excess of fair values assigned to the underlying net assets of acquired businesses.  During the nine months ended September 30, 2022, the Company acquired In2Bones Global, Inc. and Biorez, Inc. as further described in Note 4. Goodwill resulting from the In2Bones Acquisition amounted to $139.8 million and acquired intangible assets including distributor relationships and developed technology amounted to $64.9 million. Goodwill resulting from the Biorez Acquisition amounted to $59.2 million and acquired intangible assets including developed technology and trademarks and tradenames amounted to $177.9 million.

16
Other intangible assets consist of the following:

 September 30, 2022December 31, 2021
Weighted Average Amortization Period (Years)Gross
Carrying
Amount		Accumulated
Amortization		Gross
Carrying
Amount		Accumulated
Amortization
Intangible assets with definite lives:21
Customer and distributor relationships24$369,643 $(166,190)$342,452 $(152,934)
Sales representation, marketing and promotional rights25149,376 (64,500)149,376 (60,000)
Developed technology18320,204 (32,368)106,604 (26,495)
Patents and other intangible assets1578,808 (52,064)76,392 (50,890)
Intangible assets with indefinite lives:    
Trademarks and tradenames86,544 — 86,544 — 
$1,004,575 $(315,122)$761,368 $(290,319)

Customer and distributor relationships, trademarks and tradenames, developed technology and patents and other intangible assets primarily represent allocations of purchase price to identifiable intangible assets of acquired businesses. Sales representation, marketing and promotional rights represent intangible assets created under our agreement with Musculoskeletal Transplant Foundation (“MTF”).

Amortization expense related to intangible assets which are subject to amortization totaled $8.7 million and $8.3 million for the three months ended September 30, 2022 and 2021, respectively, and $24.9 million in both the nine months ended September 30, 2022 and 2021 and is included as a reduction of revenue (for amortization related to our sales representation, marketing and promotional rights) and in selling and administrative expense (for all other intangible assets) in the consolidated condensed statements of comprehensive income (loss).
 
The estimated intangible asset amortization expense remaining for the year ending December 31, 2022 and for each of the five succeeding years is as follows:
 
Amortization included in expenseAmortization recorded as a reduction of revenueTotal
Remaining, 2022$7,487 $1,500 $8,987 
202329,263 6,000 35,263 
202428,947 6,000 34,947 
202529,423 6,000 35,423 
202629,196 6,000 35,196 
202730,235 6,000 36,235 

17
Note 11 - Long-Term Debt

Long-term debt consists of the following:

 September 30, 2022December 31, 2021
Revolving line of credit$53,000 $140,000 
Term loan, net of deferred debt issuance costs of $781 and $1,373 in 2022 and 2021, respectively
133,807 226,196 
2.625% convertible notes, net of deferred debt issuance costs of $531 and $3,700 in 2022 and 2021, respectively, and unamortized discount of $23,404 in 2021
69,469 317,896 
2.250% convertible notes, net of deferred debt issuance costs of $19,898 in 2022
780,102 — 
Financing leases297 564 
Total debt1,036,675 684,656 
Less:  Current portion237 12,249 
Total long-term debt$1,036,438 $672,407 

Seventh Amended and Restated Senior Credit Agreement

On July 16, 2021, we entered into a seventh amended and restated senior credit agreement consisting of: (a) a $233.5 million term loan facility and (b) a $585.0 million revolving credit facility. The revolving credit facility will terminate and the loans outstanding under the term loan facility will expire on July 16, 2026. The term loan was payable in quarterly installments increasing over the term of the facility. During the nine months ended September 30, 2022 we made a $90.0 million prepayment on the term loan facility resulting in the elimination of such quarterly payments with the remaining balance due upon the expiration of the term loan facility. The $90.0 million prepayment was accounted for as an extinguishment and resulted in a write-off to other expense of unamortized debt issuance costs of $0.5 million. Proceeds from the term loan facility and borrowings under the revolving credit facility were used to repay the then existing senior credit agreement. Interest rates are at LIBOR (3.125% at September 30, 2022) plus an interest rate margin of 1.125% (4.250% at September 30, 2022). For borrowings where we elect to use the alternate base rate, the initial base rate is the greatest of (i) the Prime Rate, (ii) the Federal Funds Rate plus 0.50% or (iii) the one-month Adjusted LIBOR plus 1.00%, plus, in each case, an interest rate margin.

There were $134.6 million in borrowings outstanding on the term loan facility as of September 30, 2022. There were $53.0 million in borrowings outstanding under the revolving credit facility as of September 30, 2022. Our available borrowings on the revolving credit facility at September 30, 2022 were $530.2 million with approximately $1.8 million of the facility set aside for outstanding letters of credit.
    
The seventh amended and restated senior credit agreement is collateralized by substantially all of our personal property and assets. The seventh amended and restated senior credit agreement contains covenants and restrictions which, among other things, require the maintenance of certain financial ratios and restrict dividend payments and the incurrence of certain indebtedness and other activities, including acquisitions and dispositions. We were in full compliance with these covenants and restrictions as of September 30, 2022. We are also required, under certain circumstances, to make mandatory prepayments from net cash proceeds from any issuance of equity and asset sales.

2.625% Convertible Notes

On January 29, 2019, we issued $345.0 million in 2.625% convertible notes due in 2024 (the "2.625% Notes"). Interest is payable semi-annually in arrears on February 1 and August 1 of each year, commencing August 1, 2019. The 2.625% Notes will mature on February 1, 2024, unless earlier repurchased or converted. The 2.625% Notes represent subordinated unsecured obligations and are convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock.  The 2.625% Notes may be converted at an initial conversion rate of 11.2608 shares of our common stock per $1,000 principal amount of 2.625% Notes (equivalent to an initial conversion price of approximately $88.80 per share of common stock). Holders of the 2.625% Notes may convert the 2.625% Notes at their option at any time on or after November 1, 2023 through the second scheduled trading day preceding the maturity date. Holders of the 2.625% Notes will also have the right to convert the 2.625% Notes prior to November 1, 2023, but only upon the occurrence of specified events. The conversion rate is subject to anti-dilution adjustments if certain events occur. A portion of the net proceeds from the offering of the 2.625% Notes were used as part of the financing for the Buffalo Filter acquisition and $21.0 million were used to pay the cost of certain convertible notes hedge transactions as further described below.
18

On June 6, 2022, the Company repurchased and extinguished $275.0 million principal amount of the 2.625% Notes for aggregate consideration consisting of $275.0 million in cash and approximately 0.9 million shares of the Company's common stock. During the nine months ended September 30, 2022, the Company recorded a loss on extinguishment of $103.1 million to other expense based on the fair value of the shares of the Company’s common stock issued in connection with the extinguishment. This loss was not deductible for tax purposes. We also recorded a write-off to other expense of unamortized debt issuance costs related to the 2.625% Notes of $2.9 million. Concurrently, the Company entered into a Supplemental Indenture related to the remaining $70.0 million in 2.625% Notes, in which the Company irrevocably elected to settle the principal value of those 2.625% Notes in cash.

Our effective borrowing rate for nonconvertible debt at the time of issuance of the 2.625% Notes was estimated to be 6.14%, which resulted in $51.6 million of the $345.0 million aggregate principal amount of Notes issued, or $39.1 million after taxes, being attributable to equity.  For the three and nine months ended September 30, 2021, we recorded interest expense related to the amortization of debt discount on the 2.625% Notes of $2.6 million and $7.6 million, respectively, at the effective interest rate of 6.14%.  On January 1, 2022, we adopted ASU 2020-06 using the modified retrospective approach as further described in Note 3. This ASU eliminated the equity component separately recorded for the conversion features associated with the convertible notes and related debt discount. For the three months ended September 30, 2022 and 2021, we have recorded interest expense on the 2.625% Notes of $0.5 million and $2.3 million, respectively, and for the nine months ended September 30, 2022 and 2021 we have recorded interest expense on the 2.625% Notes of $4.4 million and $6.8 million, respectively, at the contractual coupon rate of 2.625%.

The estimated fair value of the 2.625% Notes was approximately $77.1 million as of September 30, 2022 based on a market approach which represents a Level 2 valuation in the fair value hierarchy. The estimated fair value was determined based on the estimated or actual bids and offers of the 2.625% Notes in an over-the-counter market transaction on the last business day of the period.

2.250% Convertible Notes

On June 6, 2022, we issued $800.0 million in 2.250% Notes. Interest is payable semi-annually in arrears on June 15 and December 15 of each year, commencing December 15, 2022. The 2.250% Notes will mature on June 15, 2027, unless earlier repurchased or converted. The 2.250% Notes represent subordinated unsecured obligations and are convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock, with the principal required to be paid in cash. The 2.250% Notes may be converted at an initial conversion rate of 6.8810 shares of our common stock per $1,000 principal amount of the 2.250% Notes (equivalent to an initial conversion price of approximately $145.33 per share of common stock). Holders of the 2.250% Notes may convert the 2.250% Notes at their option at any time on or after March 15, 2027 through the second scheduled trading day preceding the maturity date. Holders of the 2.250% Notes will also have the right to convert the 2.250% Notes prior to March 15, 2027, but only upon the occurrence of specified events. The conversion rate is subject to anti-dilution adjustments if certain events occur. A portion of these proceeds were used to repurchase and extinguish a portion of the 2.625% Notes, pay off our then outstanding balance on our revolving line of credit, pay down of $90.0 million of our term loan and partially pay for the In2Bones Acquisition. In addition, approximately $115.6 million of the proceeds were used to pay the cost of certain convertible notes hedge transactions related to the 2.250% Notes.

For the three and nine months ended September 30, 2022, we have recorded interest expense on the 2.250% Notes of $4.5 million and $5.8 million, respectively, at the contractual coupon rate of 2.250%.

The estimated fair value of the 2.250% Notes was approximately $690.3 million as of September 30, 2022 based on a market approach which represents a Level 2 valuation in the fair value hierarchy. The estimated fair value was determined based on the estimated or actual bids and offers of the 2.250% Notes in an over-the-counter market transaction on the last business day of the period.

Convertible Notes Hedge Transactions

In connection with the offering of the 2.625% and 2.250% Notes, we entered into convertible notes hedge transactions with a number of financial institutions (each, an “option counterparty”). The convertible notes hedge transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the respective Notes, the number of shares of our common stock underlying the 2.625% and 2.250% Notes. Concurrent with entering into the convertible notes hedge transactions, we also entered into separate warrant transactions with each option counterparty whereby we sold to such option counterparty warrants to purchase, subject to customary anti-dilution adjustments, the same number of shares of our common stock.

In connection with the repurchase and extinguishment of $275.0 million principal amount of the 2.625% Notes, the
19
Company entered into agreements with the option counterparties to terminate a corresponding portion of the hedges on the 2.625% Notes. The transactions had a net fair value due the Company on execution date of $22.2 million which was recorded as an adjustment to Paid-in Capital. The Company recorded a $5.5 million charge to other expense as a result of a subsequent decline in fair value between execution date and settlement date with the Company receiving net cash of $16.7 million. The termination of the convertible notes hedge resulted in the release of the related deferred tax asset. In connection with the issuance of 2.250% Notes, the Company purchased hedges for $187.6 million ($142.1 million net of tax) and received proceeds from the issuance of warrants totaling $72.0 million, recorded to paid-in capital.

The convertible notes hedge transactions are expected generally to reduce the potential dilution upon conversion of the Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, in the event that the market price per share of our common stock, as measured under the terms of the convertible note hedge transactions, is greater than the strike price of the convertible notes hedge transactions, which initially corresponds to the conversion price of the Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the Notes. If, however, the market price per share of our common stock, as measured under the terms of the warrant transactions, exceeds the strike price ($114.92 for the 2.625% Notes and $251.53 for the 2.250% Notes) of the warrants, there would nevertheless be dilution to the extent that such market price exceeds the strike price of the warrants as noted in Note 9, unless we elect to settle the warrants in cash.

The scheduled maturities of long-term debt outstanding at September 30, 2022 are as follows:

Remaining 2022$— 
2023— 
202470,000 
2025— 
2026187,588 
2027800,000 
The above amounts exclude deferred debt issuance costs and financing leases.

Note 12 – Guarantees

We provide warranties on certain of our products at the time of sale and sell extended warranties. The standard warranty period for our capital equipment is generally one year and our extended warranties typically vary from one to three years. Liability under service and warranty policies is based upon a review of historical warranty and service claim experience. Adjustments are made to accruals as claim data and historical experience warrant.

Changes in the liability for standard warranties for the nine months ended September 30, are as follows:

 20222021
Balance as of January 1,$2,344 $1,826 
Provision for warranties297 1,235 
Claims made(624)(683)
Balance as of September 30,$2,017 $2,378 
 
Costs associated with extended warranty repairs are recorded as incurred and amounted to $4.6 million and $5.2 million for the nine months ended September 30, 2022 and 2021, respectively.

20
Note 13 – Pension Plan

Net periodic pension cost consists of the following: 

Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Service cost$269 $248 $807 $744 
Interest cost on projected benefit obligation537 451 1,611 1,353 
Expected return on plan assets(1,324)(1,289)(3,972)(3,867)
Net amortization and deferral647 832 1,941 2,496 
Net periodic pension cost$129 $242 $387 $726 
 
We do not expect to make any pension contributions during 2022. Non-service pension cost/(benefit) was immaterial for the three and nine months ended September 30, 2022 and 2021.

Note 14 – Acquisition and Other Expense

Acquisition and other expense consists of the following:

Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Acquisition costs included in cost of sales$2,096 $— $2,445 $— 
Acquisition costs $3,706 $— $6,306 $— 
Legal matters— — 775 — 
Restructuring and related costs— — — 414 
Acquisition and other costs included in selling and administrative expense$3,706 $— $7,081 $414 
Convertible notes premium on extinguishment$— $— $103,125 $— 
Change in fair value of convertible notes hedges upon settlement— — 5,460 — 
Loss on early extinguishment of debt— 1,127 3,426 1,127 
Debt related costs included in other expense$— $1,127 $112,011 $1,127 

During the three and nine months ended September 30, 2022 we recognized $2.1 million and $2.4 million, respectively, in costs for inventory step-up adjustments associated with the In2Bones Acquisition, as further described in Note 4.

During the three and nine months ended September 30, 2022 we recognized $3.7 million and $6.3 million, respectively, in consulting fees, legal fees and other integration related costs associated with the acquisitions of In2Bones and Biorez, as further described in Note 4. These costs were included in selling and administrative expense.

During the nine months ended September 30, 2022, we recognized $0.8 million in costs related to the settlement of litigation. These costs were included in selling and administrative expense.

21
During the nine months ended September 30, 2021 we recorded a charge of $0.4 million related to the restructuring of our sales force which consisted primarily of termination payments to Orthopedic distributors made in exchange for ongoing assistance to transition to employee-based sales representatives and severance. These costs were charged to selling and administrative expense.

During the nine months ended September 30, 2022, we recorded expense of $103.1 million related to the conversion premium on the repurchase and extinguishment of $275.0 million of the 2.625% Notes, $5.5 million related to the settlement of the associated convertible notes hedge transactions and $3.4 million related to the write-off of deferred financing fees associated with the repurchase and extinguishment of $275.0 million of the 2.625% Notes and the pay down of $90.0 million on our term loan. These costs were recorded in other expense as further discussed in Note 11.

During the three and nine months ended ended September 30, 2021, we recorded $1.1 million related to a loss on early extinguishment and third party fees associated with the seventh amended and restated senior credit agreement. These costs were included in other expense.

Note 15 — Business Segment
We are accounting and reporting for our business as a single operating segment entity engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. Our chief operating decision maker (the CEO) evaluates the various global product portfolios on a net sales basis and evaluates profitability, investment, cash flow metrics and allocates resources on a consolidated worldwide basis due to shared infrastructure and resources. Our product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and small bone, large bone and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgery procedures and fees related to the sales representation, promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments. These product lines' net sales are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Orthopedic surgery$118,618 $105,751 $346,317 $320,809 
General surgery156,470 143,076 448,288 415,856 
Consolidated net sales$275,088 $248,827 $794,605 $736,665 

Note 16 – Legal Proceedings

From time to time, the Company may receive an information request, subpoena or warrant from a government agency such as the Securities and Exchange Commission, Department of Justice, Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, the United States Food and Drug Administration, the Department of Labor, the Treasury Department or other federal and state agencies or foreign governments or government agencies. These information requests, subpoenas or warrants may or may not be routine inquiries, or may begin as routine inquiries and over time develop into enforcement actions of various types. Likewise, if we receive reports of alleged misconduct from employees and third parties, we investigate as appropriate.

Manufacturers of medical devices have been the subject of various enforcement actions relating to interactions with health care providers domestically or internationally whereby companies are claimed to have provided health care providers with inappropriate incentives to purchase their products. Similarly, the Foreign Corrupt Practices Act ("FCPA") imposes obligations on manufacturers with respect to interactions with health care providers who may be considered government officials based on their affiliation with public hospitals. The FCPA also requires publicly listed manufacturers to maintain accurate books and records, and maintain internal accounting controls sufficient to provide assurance that transactions are accurately recorded, lawful and in accordance with management's authorization. The FCPA poses unique challenges both because manufacturers operate in foreign cultures in which conduct illegal under the FCPA may not be illegal in local jurisdictions, and because, in some cases, a United States manufacturer may face risks under the FCPA based on the conduct of third parties over whom the manufacturer may not have complete control. While CONMED has not experienced any material enforcement action to date, there can be no assurance that the Company will not be subject to a material enforcement action in
22
the future, or that the Company will not incur costs including, in the form of fees for lawyers and other consultants, that are material to the Company’s results of operations in the course of responding to a future inquiry or investigation.

Manufacturers of medical products may face exposure to significant product liability claims, as well as patent infringement and other claims incurred in the ordinary course of business. To date, we have not experienced any claims that have been material to our financial statements or financial condition, but any such claims arising in the future could have a material adverse effect on our business, results of operations or cash flows. We currently maintain commercial product liability insurance of $35 million per incident and $35 million in the aggregate annually, which we believe is adequate. This coverage is on a claims-made basis. There can be no assurance that claims will not exceed insurance coverage, that the carriers will be solvent or that such insurance will be available to us in the future at a reasonable cost.

Our operations are subject, and in the past have been subject, to a number of environmental laws and regulations governing, among other things, air emissions; wastewater discharges; the use, handling and disposal of hazardous substances and wastes; soil and groundwater remediation and employee health and safety. Likewise, the operations of our suppliers and sterilizers are subject to similar environmental laws and regulations. In some jurisdictions, environmental requirements may be expected to become more stringent in the future. In the United States, certain environmental laws can impose liability for the entire cost of site restoration upon each of the parties that may have contributed to conditions at the site regardless of fault or the lawfulness of the party’s activities. While we do not believe that the present costs of environmental compliance and remediation are material, there can be no assurance that future compliance or remedial obligations would not have a material adverse effect on our financial condition, results of operations or cash flows.

In 2014, the Company acquired EndoDynamix, Inc. The agreement governing the terms of the acquisition provides that, if various conditions are met, certain contingent payments relating to the first commercial sale of the products (the milestone payment), as well as royalties based on sales (the revenue based payments), are due to the seller. In 2016, we notified the seller that there was a need to redesign the product, and that, as a consequence, the first commercial sale had been delayed. Consequently, the payment of contingent milestone and revenue-based payments were delayed. On January 18, 2017, the seller provided notice (the "Notice") seeking $12.7 million under a liquidated damages clause, which essentially represented the seller's view as to the sum of the projected contingent milestone and revenue-based payments on an accelerated basis. CONMED responded to the Notice denying that there was any basis for acceleration of the payments due under the acquisition agreement. On February 22, 2017, the representative of the former shareholders of EndoDynamix filed a complaint in Delaware Chancery Court claiming breach of contract with respect to the duty to commercialize the product and seeking the contingent payments on an accelerated basis. In the third quarter of 2018, the Company decided to halt the development of the EndoDynamix clip applier and recorded a charge to write off assets and released a previously accrued contingent consideration liability. In court filings the Plaintiffs claim to seek liquidated damages, as well as additional damages up to $24.8 million. A non-jury trial in the Delaware Chancery Court commenced on March 18, 2021, and testimony concluded on April 7, 2021. On June 30, 2022, the Court issued a ruling that CONMED had presented overwhelming evidence that it had not breached its obligations under the acquisition agreement, and that CONMED was entitled to judgement on all claims asserted against it. The Company had not recorded any expense related to potential damages in connection with this matter and the period within which the former shareholders of EndoDynamix could have appealed expired without any appeal being filed.

CONMED is defending two Georgia State Court actions. The first action was filed in Cobb County by various employees, former employees, contract workers and others against CONMED and against a contract sterilizer (the "Cobb County Action"). The second action was filed in Douglas County against CONMED’s landlord and other allegedly related entities (the "Douglas County Action"). Plaintiffs in the lawsuits allege personal injury and related claims purportedly arising from or relating to exposure to Ethylene Oxide, a chemical used to sterilize certain products. CONMED is defending the claims asserted directly against it and is providing indemnification for certain other defendants for these claims based on contractual provisions.

Both actions are in their early stages. The Company's motion to dismiss in the Cobb County action was heard on January 10, 2022, and the Court issued a ruling on June 15, 2022 dismissing 44 of the 53 plaintiffs' claims as precluded by the exclusive workers' compensation remedy, as well as one claim from a non-employee plaintiff. As to the remaining claims that were not the subject of the motion to dismiss, CONMED believes it has strong defenses and will vigorously defend itself and all parties it is indemnifying. As with any litigation, there are risks, including the risk that CONMED may not prevail with respect to the defense of the underlying claims, or with respect to securing adequate insurance coverage for the indemnification claims. The Company is unable to estimate any range of possible loss at this time, and has not recorded any expense related to potential damages in connection with this matter because the Company does not believe any potential loss is probable.

CONMED has submitted the foregoing claims for insurance coverage. One insurer is providing coverage for certain of the claims asserted directly against the Company. CONMED is currently litigating two lawsuits in the United States District
23
Court for the Northern District of New York with Federal Insurance Company (“Chubb”): one involving CONMED’s claim for coverage for the indemnification claims arising from the Cobb County Action, and the other concerning CONMED’s claim for coverage for the indemnification claims arising from the Douglas County Action. On March 10, 2022, the Court ruled in favor of CONMED with respect to coverage for the indemnification claims arising from the Cobb County Action. Chubb's motion for reconsideration was denied, and Chubb filed a notice of appeal. On August 9, 2022, CONMED won a similar ruling finding in its favor and against Chubb as to the coverage case concerning the Douglas County Action. Chubb has appealed that decision as well. CONMED believes its position is well-grounded in the facts and the law, but there can be no assurance that CONMED will prevail in either of the two coverage cases.

In addition, one of CONMED’s contract sterilizers, which is defending toxic tort claims asserted by various residents in the areas around its processing facility, has placed CONMED on notice of a claim for indemnification relating to some of those claims. CONMED is reviewing the notice, and has not at this time taken any position on the notice.

From time to time, we are also subject to negligence and other claims arising out of the ordinary conduct of our business, including, for example, accidents our employees may experience within the course of their employment or otherwise. We are currently defending one such claim, which we expect to be fully covered by insurance, involving potentially significant personal injuries. The Company is unable to estimate any range of possible loss at this time, and therefore has not recorded any liability related to potential damages in connection with this matter.

We record reserves sufficient to cover probable and estimable losses associated with any such pending claims. We do not expect that the resolution of any pending claims, investigations or reports of alleged misconduct will have a material adverse effect on our financial condition, results of operations or cash flows. There can be no assurance, however, that future claims or investigations, or the costs associated with responding to such claims, investigations or reports of misconduct, especially claims and investigations not covered by insurance, will not have a material adverse effect on our financial condition, results of operations or cash flows.

24
Item 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
 AND RESULTS OF OPERATIONS		 
Forward-Looking Statements
 
In this Report on Form 10-Q, we make forward-looking statements about our financial condition, results of operations and business. Forward-looking statements are statements made by us concerning events that may or may not occur in the future. These statements may be made directly in this document or may be “incorporated by reference” from other documents. Such statements may be identified by the use of words such as “anticipates”, “expects”, “estimates”, “intends” and “believes” and variations thereof and other terms of similar meaning.

Forward-Looking Statements are not Guarantees of Future Performance
 
Forward-looking statements involve known and unknown risks, uncertainties and other factors, including those that may cause our actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include those identified under “Risk Factors” in our Annual Report on Form 10-K for the year-ended December 31, 2021 and the following, among others:

•general economic and business conditions;
•compliance with and changes in regulatory requirements;
•the COVID-19 global pandemic poses significant risks to our business, financial condition and results of operations, which may be heightened as the pandemic, government and hospital responses to it, continue;
•the possibility that United States or foreign regulatory and/or administrative agencies may initiate enforcement actions against us or our distributors;
•the introduction and acceptance of new products;
•the risk of an information security breach, including a cybersecurity breach;
•competition;
•changes in customer preferences;
•changes in technology;
•the availability and cost of materials, including inflation and ongoing supply chain challenges;
•cyclical customer purchasing patterns due to budgetary and other constraints;
•environmental compliance risks, including lack of availability of sterilization with Ethylene Oxide (“EtO”) or other compliance costs associated with the use of EtO;
•the quality of our management and business abilities and the judgment of our personnel, as well as our ability to attract, motivate and retain employees at all levels of the Company;
•the availability, terms and deployment of capital;
•future levels of indebtedness and capital spending;
•changes in foreign exchange and interest rates;
•the ability to evaluate, finance and integrate acquired businesses, products and companies;
•changes in business strategy;
•the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues;
•the ability to defend and enforce intellectual property, including the risks related to theft or compromise of intellectual property in connection with our international operations;
•the risk of patent, product and other litigation, as well as the cost associated with such litigation;
•trade protection measures, tariffs and other border taxes, and import or export licensing requirements; and
•weather related events which may disrupt our operations.

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations” below and “Risk Factors” and “Business” in our Annual Report on Form 10-K for the year-ended December 31, 2021 for a further discussion of these factors. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.



25
Overview

CONMED Corporation (“CONMED”, the “Company”, “we” or “us”) is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology.

Our product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and small bone, large bone and specialty powered surgical instruments as well as, imaging systems for use in minimally invasive surgery procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments. These product lines as a percentage of consolidated net sales are as follows:
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Orthopedic surgery43 %42 %44 %44 %
General surgery57 %58 %56 %56 %
Consolidated net sales100 %100 %100 %100 %

A significant amount of our products are used in surgical procedures with approximately 83% of our revenues derived from the sale of single-use products. Our capital equipment offerings also facilitate the ongoing sale of related single-use products and accessories, thus providing us with a recurring revenue stream. We manufacture substantially all of our products in facilities located in the United States and Mexico. We market our products both domestically and internationally directly to customers and through distributors. International sales approximated 45% of our consolidated net sales during both the nine months ended September 30, 2022 and 2021.

Business Environment
    
On June 13, 2022, we acquired In2Bones Global, Inc. ("In2Bones") and all of its stock (the "In2Bones Acquisition") for an aggregate upfront payment of $145.2 million in cash. In addition, there are potential earn-out payments to In2Bones’ equity holders in an amount up to $110.0 million based on the achievement of certain revenue targets for In2Bones products during the sixteen (16) successive quarters commencing on July 1, 2022. We financed the purchase through a combination of the issuance of $800.0 million in 2.250% Notes due in 2027 as further described in Note 11 and cash on hand.

On August 9, 2022, we acquired Biorez, Inc. ("Biorez") and all of its stock (the "Biorez Acquisition") for an aggregate upfront payment of $85.9 million in cash. We paid $83.1 million upon closing, with a $2.8 million purchase price adjustment holdback, pursuant to the merger agreement for the Biorez Acquisition. In addition, there are potential earn-out payments to Biorez’ equity holders in an amount up to $165.0 million based on the achievement of certain revenue targets for Biorez products during the sixteen (16) successive quarters commencing on October 1, 2022. The Biorez Acquisition was funded through a combination of cash on hand and long-term borrowings.

Refer to Note 4 for further information on the business acquisitions.

Our business has been and may continue to be impacted by the COVID-19 pandemic as variants of the virus emerge.  We believe we will continue to experience market variability as a result of the pandemic that could influence sales, suppliers, patients and customers. There remains uncertainty related to the COVID-19 pandemic, including the duration and severity of future impacts to the business and we continue to see our customers and suppliers impacted in a variety of ways. The Company is also being impacted by the macro-economic environment and we are experiencing higher manufacturing and operating costs caused by inflationary pressures and ongoing supply chain challenges. We continuously work with suppliers to mitigate these impacts; however, we expect these challenges to continue throughout 2022. This will likely impact our results of operations.

During the first three quarters of 2022, the world experienced, and continues to experience, the impact of Russia's invasion of Ukraine. The Company has no direct operations in either Russia or Ukraine and our business is limited to selling to third party distributors. Total revenues associated with sales to third party distributors in these countries are not material to the consolidated financial results, and we have fully reserved the outstanding accounts receivable from distributors in these
26
territories which are not material. We will continue to monitor and adjust our business strategy in this region as necessary. While the direct impact on the Company of Russia's invasion of Ukraine is limited, we are being affected by increases in the price of oil as a result of sanctions on Russia, which contributes to overall inflation and increased costs.

Critical Accounting Policies

Preparation of our financial statements requires us to make estimates and assumptions which affect the reported amounts of assets, liabilities, revenues and expenses. Note 1 to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year-ended December 31, 2021 describes the significant accounting policies used in preparation of the Consolidated Financial Statements. On an ongoing basis, we evaluate the critical accounting policies used to prepare our consolidated financial statements, including, but not limited to, those related to goodwill and intangible assets, contingent consideration and our pension benefit obligation.

As described above and in Note 4, the In2Bones and Biorez Acquisitions involve potential payments of future consideration that is contingent upon the acquired business reaching certain performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues. Projected revenues are based on the Company’s most recent internal operational budgets and long-range strategic plans. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within operating expense in the consolidated condensed statements of comprehensive income. Contingent consideration payments made soon after the acquisition date are classified as investing activities in the consolidated condensed statements of cash flows. Contingent consideration payments not made soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows.

Consolidated Results of Operations

The following table presents, as a percentage of net sales, certain categories included in our consolidated condensed statements of comprehensive income (loss) for the periods indicated:

 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Net sales100.0 %100.0 %100.0 %100.0 %
Cost of sales44.9 42.8 44.7 44.0 
Gross profit55.1 57.2 55.3 56.0 
Selling and administrative expense41.7 42.1 41.9 41.7 
Research and development expense4.6 4.4 4.4 4.4 
Income from operations8.8 10.7 9.0 9.8 
Interest expense3.1 3.3 2.4 3.8 
Other expense— 0.5 14.1 0.2 
Income (loss) before income taxes5.7 7.0 (7.6)5.9 
Provision (benefit) for income taxes (11.1)1.0 5.9 0.7 
Net income (loss)16.8 %6.0 %(13.5)%5.2 %

27

Net Sales

The following table presents net sales by product line for the three and nine months ended September 30, 2022 and 2021:

Three Months Ended
% Change
20222021As ReportedImpact of Foreign CurrencyConstant Currency
Orthopedic surgery$118.6 $105.7 12.2 %1.8 %14.0 %
General surgery156.5 143.1 9.4 %1.3 %10.7 %
   Net sales$275.1 $248.8 10.6 %1.5 %12.1 %
Single-use products$231.3 $200.9 15.1 %1.6 %16.7 %
Capital products43.8 47.9 -8.5 %1.2 %-7.3 %
   Net sales$275.1 $248.8 10.6 %1.5 %12.1 %
Nine Months Ended
% Change
20222021As ReportedImpact of Foreign CurrencyConstant Currency
Orthopedic surgery$346.3 $320.8 8.0 %1.0 %9.0 %
General surgery448.3 415.9 7.8 %0.9 %8.7 %
   Net sales$794.6 $736.7 7.9 %0.9 %8.8 %
Single-use products$663.1 $597.3 11.0 %1.0 %12.0 %
Capital products131.5 139.4 -5.6 %0.9 %-4.7 %
   Net sales$794.6 $736.7 7.9 %0.9 %8.8 %

Net sales increased 10.6% and 7.9% in the three and nine months ended September 30, 2022, respectively, compared to the same periods a year ago driven by increases in our product lines.

•Orthopedic surgery sales increased 12.2% and 8.0% in the three and nine months ended September 30, 2022, respectively, primarily related to growth in our sports medicine and procedures specific product offerings coupled with the sales from the recently acquired In2Bones products.

•General surgery sales increased 9.4% and 7.8% in the three and nine months ended September 30, 2022, respectively, primarily driven by the continued growth in our AirSeal and other advanced surgical product offerings as well as advanced endoscopic technologies products.

Cost of Sales

Cost of sales increased to $123.5 million in the three months ended September 30, 2022 as compared to $106.5 million in the three months ended September 30, 2021 and increased to $355.2 million in the nine months ended September 30, 2022 as compared to $324.5 million in the nine months ended September 30, 2021. Gross profit margins decreased 210 basis points to 55.1% in the three months ended September 30, 2022 as compared to 57.2% in the three months ended September 30, 2021. Gross profit margins decreased 70 basis points to 55.3% in the nine months ended September 30, 2022 as compared to 56.0% in the nine months ended September 30, 2021. Decreases in gross profit margins are driven by recognition of unfavorable production variances resulting from cost increases and inflation in raw materials, freight and other costs of production. In addition, during the three and nine months ended September 30, 2022, we incurred costs for inventory step-up adjustments of $2.1 million and $2.4 million, respectively, related to the In2Bones acquisition.

28

Selling and Administrative Expense

Selling and administrative expense increased to $114.6 million in the three months ended September 30, 2022 as compared to $104.7 million in the three months ended September 30, 2021 and increased to $333.3 million in the nine months ended September 30, 2022 as compared to $307.5 million in the nine months ended September 30, 2021. Selling and administrative expense as a percentage of net sales decreased to 41.7% in the three months ended September 30, 2022 as compared to 42.1% in the three months ended September 30, 2021 and increased to 41.9% in the nine months ended September 30, 2022 as compared to 41.7% in the nine months ended September 30, 2021.

The decrease in selling and administrative expense as a percentage of net sales for the three months ended September 30, 2022 was primarily driven by higher sales in 2022 as compared to the prior year period, which was partially offset by the $3.7 million in consulting fees, legal fees and other integration related costs associated with the In2Bones and Biorez acquisitions.

The increase in selling and administrative expense as a percentage of net sales for the nine months ended September 30, 2022 was primarily driven by $6.3 million in consulting fees, legal fees and other integration related costs associated with the acquisitions of In2Bones and Biorez as further described in Note 4 and Note 14 and $0.8 million in legal fees related to the settlement of litigation as further described in Note 14. These amounts were partially offset by the prior year having a $0.4 million related to sales force restructuring in 2021.

Research and Development Expense

Research and development expense increased to $12.8 million in the three months ended September 30, 2022 as compared to $10.9 million in the three months ended September 30, 2021 and increased to $34.9 million in the nine months ended September 30, 2022 as compared to $32.2 million in the nine months ended September 30, 2021. As a percentage of net sales, research and development expense increased 20 basis points to 4.6% in the three months ended September 30, 2022 as compared to 4.4% in the three months ended September 30, 2021 and remained flat at 4.4% in the nine months ended September 30, 2022 as compared to the nine months ended September 30, 2021. The higher spend as a percentage of sales for the three months ended September 30, 2022 was mainly driven by the In2Bones and Biorez Acquisitions as well as timing of projects.

Interest Expense

Interest expense increased to $8.5 million in the three months ended September 30, 2022 from $8.1 million in the three months ended September 30, 2021. The weighted average interest rates on our borrowings increased to 2.66% in the three months ended September 30, 2022 as compared to 2.46% in the three months ended September 30, 2021. The increase in interest expense in the three months ended September 30, 2022 is primarily driven by the increased borrowings of the 2.250% Notes offset by three months ended September 30, 2021 including $2.6 million in interest expense related to the amortization of debt discount that is no longer applicable in 2022 as a result of the adoption of ASU 2020-06, as further described in Note 3.

Interest expense decreased to $19.5 million in the nine months ended September 30, 2022 from $27.9 million in the nine months ended September 30, 2021. The weighted average interest rates on our borrowings decreased to 2.44% in the nine months ended September 30, 2022 as compared to 2.94% in the nine months ended September 30, 2021. The decrease in interest expense in the nine months ended September 30, 2022 is primarily due to decreases in our term loan and revolving credit facility borrowings; decreases in our weighted average interest rates compared to the same periods a year ago as a result of the seventh amended and restated senior credit agreement; and the nine months ended September 30, 2021 including $7.6 million in interest expense related to the amortization of debt discount that is no longer applicable in 2022 as a result of the adoption of ASU 2020-06, as further described in Note 3. These are offset by the increased borrowings of the 2.250% Notes entered into on June 6, 2022.

Other Expense

During the nine months ended September 30, 2022, we recorded expense of $103.1 million related to the conversion premium on the repurchase and extinguishment of 2.625% Notes; $5.5 million related to the settlement of the associated convertible notes hedge transactions and $3.4 million related to the write-off of deferred financing fees associated with the repurchase of $275.0 million of the 2.625% Notes and the pay down of $90.0 million on our term loan as further described in Note 11.

29
During the three and nine months ended ended September 30, 2021, we recorded $1.1 million related to a loss on early extinguishment and third party fees associated with the seventh amended and restated senior credit agreement.

Provision (Benefit) for Income Taxes

The Company's tax provision (benefit) for interim periods is determined using an estimate of its annual effective tax rate applied to its year-to-date earnings (loss), and also adjusting for discrete items arising in that quarter. In each quarter, the Company updates its estimate of the annual effective tax rate and if the estimated annual effective tax rate changes, the Company would make a cumulative adjustment in that quarter.

Income tax benefit has been recorded at an effective tax rate of (193.7)% for the three months ended September 30, 2022 compared to an income tax expense at an effective tax rate of 14.3% for the three months ended September 30, 2021. Income tax expense has been recorded at an effective rate of (77.7)% for the nine months ended September 30, 2022 as compared to 12.3% for the nine months ended September 30, 2021. The lower effective tax rates for the three and nine months ended September 30, 2022 as compared to the same periods in the prior year were primarily due to the second quarter 2022 pretax loss that was generated by the premium on extinguishment of a portion of the 2.625% Notes and the change in fair value of convertible notes hedges upon settlement as these items were not deductible for tax purposes. The three months ended September 30, 2022 and 2021 included discrete income tax benefit from stock option exercises which reduced the effective tax rate by 1.0% and 12.5%, respectively. The nine months ended September 30, 2022 included discrete income tax benefit from stock option exercises which increased the effective rate by 3.1% as compared to the tax benefit from stock option exercises which reduced the effective tax rate by 14.1% for the nine months ended September 30, 2021. A reconciliation of the United States statutory income tax rate to our effective tax rate is included in our Annual Report on Form 10-K for the year ended December 31, 2021, under Note 8 to the consolidated financial statements.

Non-GAAP Financial Measures

Net sales on a "constant currency" basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales.

Because non-GAAP financial measures are not standardized, it may not be possible to compare this financial measure with other companies' non-GAAP financial measures having the same or similar names. This adjusted financial measure should not be considered in isolation or as a substitute for reported net sales growth, the most directly comparable GAAP financial measure. This non-GAAP financial measure is an additional way of viewing net sales that, when viewed with our GAAP results, provides a more complete understanding of our business. The Company strongly encourages investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

Liquidity and Capital Resources

Our liquidity needs arise primarily from capital investments, working capital requirements and payments on indebtedness under the seventh amended and restated senior credit agreement. We have historically met these liquidity requirements with funds generated from operations and borrowings under our revolving credit facility. In addition, we have historically used term borrowings, including borrowings under the seventh amended and restated senior credit agreement to finance our acquisitions. We also have the ability to raise funds through the sale of stock or we may issue debt through a private placement or public offering.

Operating cash flows

Our net working capital position was $365.7 million at September 30, 2022.  Net cash provided by operating activities was $45.0 million and $78.0 million in the nine months ended September 30, 2022 and 2021, respectively, generated on net income (loss) of $(107.2) million and $38.1 million for the nine months ended September 30, 2022 and 2021, respectively. The change in cash provided by operating activities in 2022 as compared to 2021 was mainly driven by:

•A decrease in cash flows from accounts receivable based on the timing of sales and cash receipts;
•A decrease in cash flows from inventory as we increased inventory levels to mitigate supply chain challenges;
•A decrease in cash flows from higher incentive compensation payments; and
•An increase in cash flows from higher accounts payable during the period due to the timing of payments.

30
Investing cash flows

Net cash used in investing activities in the nine months ended September 30, 2022 increased $231.5 million from the same period a year ago primarily due to the $144.7 million payment for the In2Bones acquisition and $82.4 million for the Biorez acquisition. In addition, capital expenditures were higher at $16.1 million in the nine months ended September 30, 2022 compared to $11.7 million in the same period a year ago.

Financing cash flows

Net cash provided by financing activities in the nine months ended September 30, 2022 was $213.5 million compared to net cash used in financing activities of $60.8 million during 2021. Below is a summary of the significant financing activities impacting the change during the nine months ended September 30, 2022 compared to 2021:

•We received proceeds of $800.0 million in 2.250% Notes as further described in Note 11.
•We paid $275.0 million in aggregate principal on the repurchase and extinguishment of the 2.625% Notes as further described in Note 11.
•We had net payments on our revolving line of credit of $87.0 million, compared to $36.0 million during the nine months ended September 30, 2021 as we used proceeds from our 2.250% Notes to pay down our outstanding balance.
•We had net payments on our term loan of $93.0 million compared to $11.3 million during the nine months ended September 30, 2021 as we prepaid $90.0 million with proceeds from the 2.250% Notes.
•We paid $187.6 million to purchase hedges related to our 2.250% Notes. Partially offsetting this, were proceeds of $72.0 million from the issuance of warrants as further described in Note 11.
•We paid $69.5 million to settle warrants related to the 2.625% Notes and received $86.2 million to settle the hedges related to the 2.625% Notes as further described in Note 11.
•We paid $21.8 million in debt issuance costs mainly related to the 2.250% Notes in 2022 compared to $2.0 million in debt issuance costs related to the seventh amended and restated senior credit agreement in 2021.

Other Liquidity Matters

Our cash balances and cash flows generated from operations may be used to fund strategic investments, business acquisitions, working capital needs, research and development, common stock repurchases and payments of dividends to our shareholders. Management believes that cash flow from operations, including cash and cash equivalents on hand and available borrowing capacity under our seventh amended and restated senior credit agreement, will be adequate to meet our anticipated operating working capital requirements, debt service, funding of capital expenditures, dividend payments and common stock repurchases in the foreseeable future. In addition, management believes we could access capital markets, as necessary, to fund future business acquisitions.

The Company is also being impacted by the macro-economic environment and we are experiencing higher manufacturing and operating costs caused by inflationary pressures and ongoing supply chain challenges. As noted above, there also remains uncertainty related to the COVID-19 pandemic, including the duration and severity of future impacts to the business and we continue to see our customers and suppliers impacted by staffing shortages. We continue to monitor our spending and expenses in light of these factors. However, we may need to take further steps to reduce our costs, or to refinance our debt. See “Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year-ended December 31, 2021, for further discussion.

There were $134.6 million in borrowings outstanding on the term loan facility as of September 30, 2022. There were $53.0 million in borrowings outstanding under the revolving credit facility as of September 30, 2022. Our available borrowings on the revolving credit facility at September 30, 2022 were $530.2 million with approximately $1.8 million of the facility set aside for outstanding letters of credit.

The seventh amended and restated senior credit agreement is collateralized by substantially all of our personal property and assets. The seventh amended and restated senior credit agreement contains covenants and restrictions which, among other things, require the maintenance of certain financial ratios and restrict dividend payments and the incurrence of certain indebtedness and other activities, including acquisitions and dispositions. We were in full compliance with these covenants and restrictions as of September 30, 2022. We are also required, under certain circumstances, to make mandatory prepayments from net cash proceeds from any issuance of equity and asset sales.

On June 6, 2022, the Company repurchased and extinguished $275.0 million principal amount of the 2.625% Notes for aggregate consideration consisting of $275.0 million in cash and approximately 0.9 million shares of the Company's common
31
stock at an exchange premium cost of $103.1 million. At such time, we also settled related hedges and warrants as noted above and further described in Note 11. Concurrently, the Company entered into a Supplemental Indenture related to the remaining $70.0 million in 2.625% Notes, in which the Company irrevocably elected to settle the principal value of the remaining 2.625% Notes in cash.

On June 6, 2022, we issued $800.0 million in 2.250% Notes and irrevocably elected to settle the principal value in cash. A portion of these proceeds were used to repurchase and extinguish a portion of the 2.625% Notes, pay off our outstanding balance on our revolving line of credit on that date, pay down $90.0 million of our term loan and partially pay for our In2Bones Acquisition. At the time of this issuance, we entered into convertible note hedge transactions with a number of financial institutions for the number of shares of our common stock underlying the Notes. Concurrently with entering into the convertible notes hedge transactions, we also entered into separate warrant transactions with each option counterparty whereby we sold to such option counterparty warrants to purchase, subject to customary anti-dilution adjustments, the same number of shares of our common stock. Refer to Note 11 for further details.

See Note 11 for further information on our financing agreements and outside debt obligations.

Our Board of Directors has authorized a $200.0 million share repurchase program. Through September 30, 2022, we have repurchased a total of 6.1 million shares of common stock aggregating $162.6 million under this authorization and have $37.4 million remaining available for share repurchases. The repurchase program calls for shares to be purchased in the open market or in private transactions from time to time. We may suspend or discontinue the share repurchase program at any time. We have not purchased any shares of common stock under the share repurchase program during 2022. We have financed the repurchases and may finance additional repurchases through operating cash flow and from available borrowings under our revolving credit facility.

New accounting pronouncements

See Note 3 to the consolidated condensed financial statements for a discussion of new accounting pronouncements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no significant changes in our primary market risk exposures or in how these exposures are managed during the nine months ended September 30, 2022.  Reference is made to Item 7A. of our Annual Report on Form 10-K for the year ended December 31, 2021 for a description of Qualitative and Quantitative Disclosures About Market Risk.
 
Item 4.  Controls and Procedures
 
As of the end of the period covered by this report, an evaluation was carried out by CONMED Corporation’s management, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934).  Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that these disclosure controls and procedures were effective as of the end of the period covered by this report.  In addition, no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) occurred during the quarter ended September 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.


PART II OTHER INFORMATION


Item 1. Legal Proceedings

Reference is made to Item 3 of the Company’s Annual Report on Form 10-K for the year-ended December 31, 2021 and to Note 16 of the Notes to Consolidated Condensed Financial Statements included in Part I of this Report for a description of certain legal matters.


32

Item 6. Exhibits

Exhibit Index
Exhibit No.Description of Exhibit
31.1
  
31.2
  
32.1
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema Document
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
101.LABXBRL Taxonomy Extension Label Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page - Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document (included in Exhibit 101)
33
SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on the date indicated below.

 CONMED CORPORATION
 
  
 
By: /s/ Todd W. Garner
 Todd W. Garner
 Executive Vice President and
 Chief Financial Officer
 
 Date:  
 October 27, 2022
34
CONMED (NYSE:CNMD)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more CONMED Charts.
CONMED (NYSE:CNMD)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more CONMED Charts.